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CHAPTER 1
INTRODUCTION AND GENERAL 
OUTLINE OF THE THESIS 
Chapter 1  
12
Infective endocarditis is a relatively rare disease which makes it difficult to 
study. Randomized controlled trials are extremely rare and only a handful 
were ever conducted. Most research in the field is being performed in tertiary 
or referral centers. In the second chapter of this thesis we present a study on 
infective endocarditis performed in general hospitals. Studies like these present 
a representation of an all-comers population and illustrate that mortality and 
morbidity might be higher than first anticipated due to underrepresentation in 
studies performed in centers with surgical intervention as an option.
In the third chapter of this thesis we seek to answer a very controversial question: 
Is chemoprophylaxis for endocarditis effective in preventing this devastating 
disease. In 2009 the European Society of Cardiology guidelines for endocarditis 
saw a dramatic change; indication for  prophylaxis was limited to a select 
population. Since that same time there has been a rise in endocarditis incidence 
and a simultaneous increase in enterococci mediated endocarditis. In this chapter 
we demonstrate this on the basis of Dutch endocarditis incidence and we advocate 
a return to the previous broader indications for chemoprophylaxis (chapter 3B).
The fourth chapter illustrates how to handle patients who have an infected 
pacemaker and who are dependent on that pacemaker at the same time. We 
describe a novel implantation strategy in which  the infected device is extracted 
while an epicardial device is implanted via mini-thoracotomy in the same 
procedure, thus ensuring permanent pacing in pacemaker dependent patients. 
The fifth chapter of this thesis tackles the incidence and outcome of infective 
endocarditis after trans-catheter aortic valve implantation (TAVI) in a multi-
centre study. It illustrates that infective endocarditis after TAVI has a relatively 
low incidence, yet outcome is poor when contracted, albeit better than surgically 
implanted prosthetic valve endocarditis.
The sixth chapter describes the outcome of cardiac failure after surgery for 
infective endocarditis. Patients who develop cardiac failure can be supported with 
veno-arterial extra corporeal membrane oxygenation (VA-EMCO). This is a form of 
mechanical circulatory support using an centrifugal pump to generate flow across 
a membrane to oxygenate the blood and supply circulatory support. 
Imaging skills are pivotal in managing these patients. This is illustrated by the case-
report in chapter 6B.
Introduction and general outline of the thesis
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VA-ECMO can also be used in patients suffering from cardiogenic shock due to 
ST-elevation myocardial infarction. This subject is addressed  in chapter seven. 
Using various predictive scores we illustrate that outcome in this group of patients 
is much better than predicted and that VA-ECMO might be a solution in treating 
patients with severe cardiogenic shock due to ST-elevation myocardial infarction. 
In the eight chapter of this thesis we describe the use of prophylactic VA-ECMO to 
support elective patients undergoing high risk PCI in whom cardiac failure is to be 
expected. It can be used safely and successfully in aiding high risk percutaneous 
coronary interventions. 
One of the drawbacks of VA-ECMO is that it increases afterload. This may 
influence outcome as it stresses the left ventricle which is a predictor for outcome 
in cardiogenic shock. In the ninth and final chapter we present the outcome of 
patients undergoing VA-ECMO treatment combined with the intra-aortic balloon 
pump (IABP) when compared to VA-ECMO alone and illustrate that combining the 
two techniques seems to lead to a better outcome through the combined actions 




PROGNOSTIC FACTORS IN 
INFECTIVE ENDOCARDITIS IN 
GENERAL HOSPITALS IN THE 
NETHERLANDS
FS van den Brink, J Hasenaar,V Winia, M Klomp, B van Vlies, D Nicastia, 
B Groenmeijer, R.Braam, W Jaarsma, A Funke Kupper 





Despite advances in treatment, infective endocarditis (IE) still ranks amongst the 
most lethal infectious diseases. We sought to determine prognostic factors in 
general hospitals in the Netherlands as research in this setting is scarce.
RESULTS
Between 2004 and 2011, we identified 216 cases of IE, 30.1% of which were 
prosthetic valve IE. This leads to an annual incidence of IE of 5.7 new cases per 
100,000 persons per year.
Women were less likely to undergo surgical intervention (OR=1.96, 95% CI 1.06-
3.61, p=0.031). Also, ageing was an independent prognostic factor for not receiving 
surgery in a multivariate analysis (annual OR=1.04, 95% CI 1.02-1.06, p<0.001). 
Female sex was a prognostic factor for mortality (OR=2.35, 95% CI 1.29-4.28, 
p=0.005). Age was also an independent prognostic factor for mortality (OR=0.95, 
95% CI 0.93-0.97, p<0.001). Conservative treatment was a prognostic factor for 
mortality (OR=3.39, 95% CI 1.80-6.38, p<0.001) whereas surgical intervention was 
an independent prognostic factor for adverse events (OR=0.33, 95% CI 0.18-0.61, 
p<0.001). Staphylococcus aureus was an independent prognostic factor for adverse 
events (OR=2.05, 95% CI 1.10-3.84, p=0.024) but not for mortality.
CONCLUSION
This study shows that endocarditis in general hospitals has a high rate of morbidity 
and mortality. Even when treated, it ranks as one of the most lethal infectious 
diseases in the Netherlands, especially in women and the elderly.
KEYWORDS
Endocarditis; Survival analysis; Hospitals, general; Mortality; Morbidity; 
Staphylococcus aureus




Since William Osler first described ‘malignant endocarditis’ in 1885, there has been 
an evolution in the pathophysiology and treatment of this rare but often lethal 
disease [1,2,3,4].
A decreased incidence of rheumatic heart valve disease but increased incidence 
of degenerative heart valve disease has changed the demographics of 
patients affected with infective endocarditis (IE) in the Western world [5,6,7,8]. 
Interestingly, in the Netherlands, due to lower numbers of intravenous drug users, 
the frequency of right-sided endocarditis has notably dropped [9]. At the same 
time, the worldwide rise in methicillin-resistant staphylococcus aureus (MRSA) 
has augmented MRSA-related IE [10,11,12,13,14,]. Furthermore, there has been 
a substantial increase in the use of prosthetic heart valves, both mechanical 
and biological [15]. Also, the increased use of devices such as pacemakers and 
implantable cardiac defibrillators is posing new challenges [10].
Previous studies in the Netherlands that assess the treatment of IE enrolled 
patients who were treated in a tertiary hospital [16,17,18,19]. One can hypothesise 
that patient demographics and outcome between a general and a tertiary hospital 
differ due to patient selection and available treatment modalities. Our experience 
is that an IE population in a tertiary centre will largely consist of patients eligible 
for surgical intervention or those who have undergone an operation. There will 
be very few patients who receive conservative treatment. A general hospital’s 
population, on the other hand, will mainly consist of patients who receive 
conservative treatment and a few patients recovering from an earlier operation. 
However, studies focussing on IE in general hospitals are scarce [20]. The primary 
aim of our study is to describe the demographics and identify the prognostic 
factors of IE in general hospitals in the Netherlands.
Furthermore, a changing insight into the demography and prophylaxis of IE 
[16,17] has led to the development of the 2009 European Society of Cardiology 
(ESC) guideline on prevention, diagnosis and treatment of IE [21]. The result of this 
guideline has been a less strict use of prophylaxis. The secondary aim of this study 
is to evaluate implementation of the revised guideline on the prevention of IE in 




A multicentre retrospective cohort study was performed in three general hospitals 
in the Netherlands (Spaarne (former Kennemer) Gasthuis Haarlem, Gelre Hospital 
Apeldoorn, Gelre Hospital Zutphen). Data collection was performed between 
2012 and 2013. Patients treated for IE were identified using the Dutch national 
in-hospital insurance registry (Diagnose Behandel Combinatie). All patients 
treated for definite or possible IE between 2004 and 2011 were included. All 
patient charts, echocardiogram reports and microbiology reports were reviewed. 
Median follow-up was 4.2 years (0.3-8.0). The modified Duke criteria were applied 
to identify patients with definite IE [21]. Patients with possible IE, according to 
the modified Duke criteria, but treated as definite IE were also included. Patients 
with native and/or prosthetic valve IE were enrolled as well as pacemaker device 
and/or lead infection. The treating cardiologist evaluated the transthoracic and 
transoesophageal echocardiograms and identified the valve or lead vegetation. 
MRSA was defined as such after consultation with a microbiologist or when another 
antibiotic was used than the first-line therapy according to the local guidelines.
Mortality was defined as all-cause mortality within the follow-up period. Adverse 
events were defined as IE-related adverse events during hospitalisation requiring 
medical intervention or prolonging hospital stay. The adverse events included 
were infarction (including stroke and peripheral septic emboli), bleeding, recurrent 
endocarditis, tachyarrhythmias and abscess formation at any location.
Statistical analysis was performed using SPSS (I.B.M. Armonk, NY, USA) and 
R (www.r-project.org). Student’s t test was used for continuous variables and 
Fisher’s exact test/Chi-square test for categorical variables. Multivariate logistic 
regression analyses were performed to determine independent risk factors for 
mortality and morbidity. A two-tailed p value of p<0.05 or less was considered 
statistically significant.
As this is a retrospective study approval of the local ethics committee was not 
needed. 





Between 2004 and 2011, we identified 216 cases of IE (Fig. 1). Based on the three 
general hospitals and the per-hospital catchment area, this would amount to an 
annual incidence of IE of 5.7 new cases per 100,000 persons per year [22,23]. The 
mean age at the time of the diagnosis was 67.5 years (22-97). Men were more 
affected than women: 62.5% versus 37.5%. Definite IE was diagnosed in 82.8% of 
the patients. Transthoracic echocardiogram confirmed the diagnosis in 19.4% of 
the cases and trans-oesophageal echocardiogram in 74.1%. In 6.5% no vegetation 
was visible. A total of 44% of the population did not have a predisposing risk factor 
for IE.
Figure 1: Number of patients admitted per year with endocarditis
Affected valves 
One-third of the patients had prosthetic valve IE (30.1%). A pacemaker device 
lead located at the right side of the heart was affected in 17 cases. In these 17 
cases a left-sided heart valve was also involved in 2 patients. Only 10 patients had 





Positive blood cultures were found in 90.7% of the patients. A total of 30.1% of all 
patients had Staphylococcus aureus in 1 or more blood cultures, making it the most 
prevalent microorganism. There was only 1 patient with a MRSA positive culture. 
A bacterial access location was found in 115/216 (53.2%) of the patients. The most 
prevalent access locations were oropharyngeal (30/115, 26.0%) cutaneous (23/115 
20.0%), urinary tract (12/115 10.4%) and the colon (10/115, 8.7%). There were only 
2 patients with intravenous drug use as a cause of their IE. 
Surgical versus conservative treatment
A total of 84 (38.9%) patients were accepted for surgical intervention. Eight 
underwent only pacemaker lead extraction. S. aureus endocarditis or prosthetic 
valve IE were not independent prognostic factors for receiving surgical 
intervention. Women were less likely to undergo a surgical intervention (OR=1.96, 
95% CI 1.06-3.61, p=0.031). Also, ageing was an independent prognostic factor for 
not receiving surgery in a multivariate analysis (annual OR=1.04, 95% CI 1.02-1.06, 
p<0.001) (Table 1). 
Table 1. Prognostic factors for conservative treatment, multivariate analysis
Female sex OR = 1.96, 95% CI 1.06-3.61, p=0.031
Age (per life year) OR = 1.04, 95% CI 1.02-1.06, p<0.001
Outcomes
All-cause mortality was 36.1%. Mortality in women was significantly higher than in 
men (49.3% versus 28.2%, p=0.002). Female sex was an independent prognostic 
factor for mortality (OR=2.35, 95% CI 1.29-4.28, p=0.005). The mean age at time of 
death was 76 years while the mean age for the surviving patients was 65 (p<0.001, 
95% CI 4.66-12.15). Age was an independent prognostic factor for mortality as well 
(OR=0.95, 95% CI 0.93-0.97, p<0.001 per life year) (Table 2). Age and gender were 
not independent prognostic factors for adverse events. 
Prognostic factors in infective endocarditis in general hospitals in the Netherlands. 
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Table 2. Prognostic factors for mortality, multivariate analysis
Age (decreased survival per life year) OR = 0.95, 95% CI 0.93-0.97, p<0.001
Female sex (decreased survival) OR = 2.35, 95% CI 1.29-4.28, p=0.005
Conservative treatment OR = 3.39, 95% CI 1.80-6.38, p<0.001
S. aureus was an independent prognostic factor for adverse events (OR=2.05, 95% 
CI 1.10-3.84, p=0.024) but not for mortality (OR=1.90, 95% CI 0.99-3.66, p=0.054) 
(Table 3).
Mortality was higher in prosthetic valve IE 42/65 (66.2%) when compared with native 
valve IE 56/151 (37.0%) (p<0.001). In a multivariate analysis between prosthetic 
valve IE versus native valve IE there were no significant differences in mortality 
and adverse events. Mortality was higher in the conservative treatment group 
62/132 (46.9%) when compared with the surgical group; 16/84 (19.0%) (p=<0.001). 
Conservative treatment was an independent prognostic factor for mortality 
(OR=3.39, 95% CI 1.80-6.38, p<0.001) (Table 2). The incidence of adverse events 
was higher in the surgical group (62/84, 73.8%) than in the conservative treatment 
group (64/132, 48.4%). Surgical intervention was an independent prognostic factor 
for adverse events (OR=0.33, 95% CI 0.18-0.61, p<0.001) (Table 3).
Table 3. Prognostic factors for adverse events, multivariate analysis
Staphylococcus aureus infection OR = 2.05, 95% CI 1.10-3.84, p=0.024
Surgical treatment OR = 0.33, 95% CI 0.18-0.61, p<0.001
Introduction of new ESC guideline
Our study includes 126 patients before and 90 patients after the introduction of 
the new ESC guideline on the prevention, diagnosis and treatment of IE. Amongst 
these patients, we did not find an evident increase in incidence of IE before and 
after the introduction of the new ESC guideline. Comparing the population before 
and after introduction of the new guideline there was no difference in mortality 
(OR=1.82, 95% CI 0.97-3.50, p=0.0665) or the number of adverse events (OR=0.60, 
95% CI 0.34-1.04, p=0.0698). There was no significant difference in the chance 
of receiving a surgical intervention before and after the introduction of the ESC 




To our knowledge this is the first multicentre retrospective cohort study on IE 
performed only in general hospitals in the Netherlands. This research shows 
that overall mortality associated with IE is higher than in other recent studies 
[16,17,18,19]. As there is no selection bias due to referral for possible surgical 
intervention we believe that, despite improvements in treatment, mortality still 
remains high and makes IE one of the most lethal infectious diseases in the 
Western world. 
Although this study focuses on all-cause mortality it does show there might be an 
underestimation of IE-related mortality based on the rates from previous studies 
[16,17,18,19]. As stated in our introduction, patient demographics and outcomes 
between general hospitals and tertiary hospitals differ: more patients who are not 
eligible for operation will remain in a general hospital and will receive conservative 
treatment. Our study shows that conservative treatment is related to a higher 
mortality, hence a possible explanation for the high overall mortality rates. Female 
sex is a prognostic factor for mortality but not for adverse events. Our study shows 
that women are less likely to receive surgical intervention. As this study also shows 
that surgical intervention has a better prognosis, this may be an explanation why 
mortality in women is higher than in men. Earlier surgical intervention may be the 
key to improving survival in women with IE. Previous studies endorse our results, 
stating that surgical intervention improves survival and adverse event-free interval 
[2,24] .
Prosthetic valve IE has a higher mortality when compared with native valve IE, 
but our study does not show a difference in adverse events between prosthetic 
and native valves. This might be explained by the population in general hospitals 
in which patients will not be eligible for surgical intervention due to existing 
comorbidities and therefore will not receive surgery. As surgery is no longer an 
option, they may have entered a palliative setting in which there was no further 
recording of adverse events and as such a possible loss to follow-up. A similar 
mechanism may explain the difference in mortality and adverse events between 
surgical treatment and conservative treatment. Patients who received surgery 
possibly had a better preoperative physical condition and therefore had higher 
survival rates. As the monitoring postoperatively might be better when compared 
with conservative treatment, there could have been an earlier detection of 
Prognostic factors in infective endocarditis in general hospitals in the Netherlands. 
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adverse events. Patients who received conservative treatment may have entered 
a palliative setting in which there was no further recording of adverse events. 
 S. aureus IE increases the risk of disease-related morbidity. As S. aureus spread is 
increasing in the population, this is a growing concern and may lead to a higher 
disease burden in the future. Fortunately, MRSA does not yet pose a significant 
problem in IE. The fact that MRSA has hardly penetrated the endocarditis 
population does not mean that it will not do so in the future. In a number of cases 
in our cohort no organism was cultured. This might be due to antibiotics having 
been started by a general practitioner prior to presentation in a hospital.
Although we do not see a difference in the number of new cases, mortality, adverse 
events and number of surgical interventions between the era before and after 
the introduction of the new ESC guidelines, this may be due to the small sample 
size. Other recent studies have shown an increase in incidence in IE related to the 
introduction of the  National Institute of Clinical Excellence 2008 guideline and 
the America College of Cardiologist/American Heart Association 2007 guidelines 
[25,26]. We expect the Dutch population to be similar to the ones described 
by Pant et al. and Dayer et al. and think a similar change in the prevalence of 
endocarditis might have taken place in the Netherlands since the introduction of 
the guidelines.
The study design, a multicentre retrospective cohort study, is a limitation to this 
study. The difference in time of follow-up of the patients included varies widely 
and as such might have influenced the numbers for mortality and adverse effects. 
CONCLUSION
This research shows that the endocarditis in general hospitals has a high rate of 
morbidity and mortality. Even when treated it ranks as one of the most lethal 
infectious diseases in the Netherlands, especially in women and the elderly. Further 
investigation is needed to determine optimal treatment and the effectiveness of 
the new ESC Guideline on the prevention, diagnosis and treatment of infective 
endocarditis.
Funding: None.
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After the introduction of the ESC guidelines on Prevention, Diagnosis and 
Treatment of Infective Endocarditis (IE) in 2009 prophylaxis for patients at risk 
became less strict. 
We hypothesise that there will be a rise in IE after the introduction of the guideline 
update.
Methods and Results:
We performed a nation-wide retrospective trend study using segmented 
regression analysis of the interrupted time series. The patient data were obtained 
via the national healthcare insurance database which collects all the diagnoses 
nationwide. We compared the data before and after the introduction of the 2009 
ESC guideline. 
Between 2005 and 2011 a total of 5213 patients were hospitalized with IE in the 
Netherlands. During this period there was a significant increase in IE from 30.2 
new cases per 1,000,000 in 2005 to 62.9 cases per 1,000,000 in 2011 (p<0.001). 
In 2009 the incidence of IE increased significantly above the projected historical 
trend (Rate Ratio: 1.327, 95% CI: 1.205 - 1.462 p<0.001). This coincides with the 
introduction of the 2009 ESC guideline. After the introduction of the ESC guideline 
the Streptococci positive cultures increased significantly in the following years 
2010-2011 from 31.1% to 53.2% (p=0.0031).
Conclusion:
This observational study shows that there has been a steady increase in the 
IE incidence between 2005 and 2011. After the introduction of the 2009 ESC 
guidelines the incidence increased more than expected from previous historical 
trends. Furthermore there was a significant increase in Streptococci related IE 
cases. 
Key words: Endocarditis, Prevention, Guidelines




Infectious endocarditis (IE) is one of the most lethal infectious diseases in the 
western world with mortality rates ranging from 20% to 75% (1-4). This underlines 
the importance of prevention of this devastating disease. The role of prophylaxis 
however is controversial and there is much debate on the strictness of its use in 
patients at risk. 
In 2007 the American College of Cardiologist/American Heart Association (ACC/
AHA) introduced the revised guideline on the treatment of infectious endocarditis 
(5). This was followed in 2008 by the National Institute of Clinical Excellence (NICE) 
guidelines (6,7). The European Society of Cardiology (ESC) followed in 2009 and in 
2015 with the new guidelines on Prevention, Diagnosis and Treatment of Infective 
Endocarditis (IE) (8,9). A result of all three revised guidelines was a much less strict 
policy regarding the use of prophylaxis in patients at risk of developing IE. Before 
these revisions virtually all patients with valvular anomalies received antibacterial 
prophylaxis while after the revision this was only in patients with previous IE, 
prosthetic heart valves and cyanotic congenital heart disease indicated. The 2007 
ACC/AHA and the 2009 ESC guidelines use virtually the same criteria in determining 
the indications for prophylaxis (5,8). Recently the ESC published a new endocarditis 
guideline in which the indications for prophylaxis remained unchanged (9). 
In early 2015 Dayer et al demonstrated that since the introduction of the NICE 
guideline there has been a drop in the use of prophylaxis and at the same time 
there has been a rise in the incidence of IE (10). Later that year Pant et al showed 
a similar trend for the Streptococcus related IE incidence in the United States (11). 
In Europe there is scant evidence on the IE incidence after the introduction of the 
revised and updated IE guidelines (12). 
With an aging population and an increase in the use of invasive medical  techniques 
there is an increase in IE in the developed world (3,10-16). As the use of prophylaxis 
is greatly reduced we hypothesize that the increase of IE will project above the 
historical trend after the introduction of the 2009 ESC guideline.
Furthermore a more detailed analysis of individual patients from three general 
hospitals gives insight into a population which is not biased by referral to a tertiary 




We performed a nation-wide retrospective secular trend study analysed as an 
interrupted time series to investigate the incidence of IE in the Netherlands. Data 
collection took place between 2012 and 2014 and the median follow up was 4.2 
years (range 0.3-8.0 years). Patients were identified using the insurance database 
between 2005 and 2011. Data were extracted by the Dutch Healthcare Authority 
(Nederlandse Zorg Autoriteit). Individual patients were anonymized but represent 
unique individual patients. This was done in order to exclude the possibility of 
duplicate entry of patients as two different hospitals could claim revenue’s for 
treating the same patient (e.g. one hospital diagnosed and one hospital operated 
and treated the patient afterwards). This insurance database has a code uniquely 
for IE. The Dutch insurance system changed its registration after 2011 and therefore 
patients after this period could not be included in this analysis. Annual incidence 
was corrected for the annual population growth according to the National Bureau 
of Statistics (Centraal Bureau voor de Statistiek). 
At the same time IE patients in three general hospitals in the Netherlands 
(Spaarne (former Kennemer) Gasthuis Haarlem, Gelre Hospital Apeldoorn, Gelre 
Hospital Zutphen) were used as a sample. These patients were identified using 
the in-hospital registration of the insurance data that was used to identify patients 
nationwide. All patient records were reviewed in order to determine patient 
characteristics such as age, gender, previous medical history, affected valves, 
organisms, micro-organism access location, mortality and morbidity. Patients 
with possible IE but treated as definite IE according to the modified Duke’ criteria 
were included (e.g: surgical intervention or 6 weeks antibiotic treatment). A small 
amount of patients in our sample population (5.1%) had disease onset in 2004 
but ended their hospitalisation in 2005 and were therefore coded according to 
insurance database. These patients were included in this research in order to 
achieve the largest possible sample size. In order to minimize potential selection 
bias which would affect a representative sample of the general population in 
the Netherlands the choice was made to select general hospitals only instead of 
tertiary centres where patients are being referred to for surgical intervention. 
As this is a retrospective study, according to Dutch law (Wet Medisch-
Wetenschappelijk Onderzoek met Mensen) an evaluation by a local medical ethical 
committee was not necessary. 
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Mortality was defined as all-cause mortality within the follow-up period. Adverse 
events weredefined as IE-related adverse events during hospitalization requiring 
medical intervention or prolonging hospital stay. The adverse events included 
were thrombo-embolic events  (including stroke and peripheral septic emboli), 
bleeding, recurrent endocarditis, tachyarrhythmia’s and abscess formation at any 
location.
Statistical analysis was performed using SPSS (I.B.M. Armonk, NY, USA) and 
R (www.rproject.org). Student’s t test was used for continuous variables and 
Fishers exact test/Chi-square test for categorical variables. Multivariate logistic 
regression analyses were performed to determine independent risk factors for 
mortality and morbidity. Multivariate analysis included affected valves, micro-
organism, age and sex.  Furthermore, on the nation-wide date a secular trend 
study analysed as an interrupted time series was performed. Rate Ratios were 
used to determine significant changes in male to female ratios and the incidence 
after the introduction of the 2009 ESC guideline. A two tailed P value of P<0.05 was 
considered statistically significant.
RESULTS:
The incidence of IE after the 2009 ESC guideline intro-
duction. 
Between 2005 and 2011 a total of 5213 patients were hospitalized with IE in 
the Netherlands. During this period there was a significant increase in infective 
endocarditis from 30.2 new cases per 1,000,000 in 2005 to 62.9 cases per 1,000,000 
in 2011 (p<0.001). Historically more male subjects are affected with IE; 69.9% of 
the patients in our population were men. The increase in IE was similar in both 
sexes. The male to female ratio remained consistent during the study period and 
was similar in the overall cohort as well as in our sample as mentioned earlier (see 
figure 1).
In 2009 the incidence of IE increased significantly above the projected historical 
trend (Rate Ratio: 1.327, 95% CI: [1.205 - 1.462] p<0.001) (see figure 2). This coincides 
with the introduction of the 2009 ESC guideline. The rise in incidence was mainly 
driven by the increase in IE incidence in men in which the significant increase in 
incidence falls in the same year as the introduction of the ESC guidelines (Rate 
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Ratio: 1.360 95% CI: [1.211-1.529] p<0.001) (see figure 3). In the female cohort a 
similar significant trend was observed only this was seen one year (2008) before 
the introduction of the ESC guideline (RR: 1.254 95% CI: [1.053-1.496] p=0.005) (see 
figure 4). 
Figure 1: Male to female rate ratios for the national cohort
Increased incidence of infective endocardiytis after the 2009 European Society 
 3A
33 
Figure 2: Nation-wide retrospective secular trend analysed as an interrupted time series; 
(Rate Ratio: 1.327, 95%, CI: [1.205 - 1.462] p<0.001) for 2009. The horizontal line indicates the 
average IE incidence before and after the 2009 ESC guideline update.
Figure 3: Nation-wide retrospective secular trend analysed as an interrupted time series in 
men only (Rate Ratio: 1.360 95%, CI: [1.211-1.529] p<0.001)  for 2009. The horizontal line 
indicates the average IE incidence before and after the 2009 ESC guideline update.
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Figure 4: Nation-wide retrospective secular trend analysed as an interrupted time series in 
women only (Rate Ratio: 1.254 95%, CI: [1.053-1.496] p=0.005) for 2008. The horizontal line 
indicates the average IE incidence before and after the 2009 ESC guideline update.
Patient characteristics of the sample population.
Three hospitals were chosen to analyse in detail as a representative sample of the 
general population. Between 2005 and 2011 we identified 216 individual cases of 
IE. Based on the three general hospitals and the per-hospital catchment area this 
would amount to an annual incidence of IE of 5.7 new cases per 100,000 persons 
per year. This incidence is similar to the nation-wide incidence. The mean age at 
the time of the diagnosis was 67.5 years (22-97). Men were more often affected 
than women; 62.5% versus 37.5% in our total sample population which was not 
statistically significantly different from the nation-wide cohort (p=0.45). Definite IE 
according to the modified Duke’ criteria was diagnosed in 82.8% of the patients. 
Trans Thoracic Echo (TTE) confirmed the diagnosis in 19.4% of the cases and 
Trans Oesophageal Echo (TOE) in 74.1%. In 6.5% of the patients no vegetation 
was visible. A total of 40.7% of the patients had a pre-existing valvular condition 
predisposing for IE.
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Introduction of the 2009 ESC guideline.
Comparing the population before and after introduction of the new guideline there 
was no difference in mortality (OR = 1.82, 95 % CI: [0.97–3.50] p = 0.0665) or the 
number of adverse events (OR = 0.60, 95 % CI: [0.34–1.04] p = 0.0698). There was 
no significant difference in the chance of receiving a surgical intervention before 
and after the introduction of the ESC guideline. However there was a significant 
difference in the mean age of the surviving patients before and after the guideline 
(see table 1). Furthermore the streptococci related infective endocarditis increased 
after the introduction of the 2009 guideline from 31.1% to 53.2% (p=0.0031) (see 
table 1). Of the whole cohort only 1/216 (0.46 %) patient had received prophylaxis.
Baseline characteristics P value
National Cohort






Male 97 (63%) 36 (58%) P= 0.53
P=0.45 (compared to 
national cohort)
Mean age 66.4 (22-97) 69.9 (40-95) P=0.10
Pre-existing valvular disease 
(excluding prosthetic valves)
18 (11.6%) 12 (19.3%) P=0.19
Pre-existing prosthetic heart 
valve
46 (29.9%) 19 (30.6%) P=1.00
Mean age at time of death 72.6 (42-97) 73.5 (54-85) P=0.75
Mean age living patients 62.7 (22—89) 68.2 (40-95) P=0.048
Mortality 58 (37.1%) 20 (32.2%) P=0.53
Positive culture 138 (89.6%) 58 (93.5%) P=0.44
Streptococci positive culture 48 (31.1%) 33 (53.2%) P=0.0031
Staphylococci positive culture 55 (35.7%) 23 (37.0%) P=0.87
Mitral Valve IE 57 (37.0%) 19 (30.6%) P=0.43
Aortic Valve IE 71 (46.1%) 26 (41.9%) P=0.65
Tricuspid Valve IE 9 (5.8%) 0 (0%) P=0.062
Pulmonary Valve IE 0 (0%) 1 (1.6%) P=0.28
Prosthetic Aortic Valve IE 27 (17.5%) 13 (20.9% P=0.56
Prosthetic Mitral Valve IE 33 (21.4%) 8 (12.9%) P=0.13
Pacemaker device lead IE 13 (8.4%) 4 (6.4) P=0.78
Definite IE (Duke’critera) 127 (82.5%) 52 (85.9%) P=1.00
Possible IE (Duke’critera) 27 (17.5% ) 10 (16.1%) P=1.00
Table 1: Baseline characteristics. Please note: various patients had multiple infected valves. 




One third of the patients had prosthetic valve IE (30.1%) all of which were left sided. 
A pacemaker device lead located at the right side of the heart was affected in 7.9% 
of the cases. In 0.9% there was a combined infection of a left sided heart valve and 
a pacemaker device lead. Only 4.6% patients had isolated tricuspid or pulmonary 
valve IE, none of which were related to a pacemaker device lead infection. One 
patient had an infected myxoma. 
Microbiology:
Positive blood cultures were present in 90.7% of the patients. In 36.1% of our 
population a staphylococcus was the pathogen. A total of 30.1% of all patients 
had Staphylococcus Aureus (SA) cultured making it the single most prevalent 
microorganism. Of the entire population only 0.5% of the positive cultures was a 
Methycilline Resistant SA. The total amount of various streptococci was 37.4%. S. 
Mitis was the single most prevalent streptococcus at 8.3%, S. Bovis (Galloliticus) 
ranked second at 6.0%. A bacterial access location was found in 53.2% of the 
patients. The most prevalent access locations were oropharyngic (13.8%) 
cutaneous (10.6%), urinary tract (5.6%) and the colon (4.6%). 
OUTCOMES
Mortality:
All-cause mortality was 36.1%. The mortality in women was significantly higher 
than in men
(49.3% versus 28.2%, p=0.002). Female sex was an independent prognostic factor 
for mortality (OR=2.35, 95% CI: [1.29-4.28] p=0.005). The mean age at time of death 
was 76 while the mean age for the surviving patients was statically significantly 
lower at 65 (P<0.001 CI: [4.66-12.15]). Age was also an independent prognostic 
factor for mortality (per life year OR=1.05, 95% CI: [1.03-1.08] p<0.001) (see table 
2). Age and gender weren’t independent prognostic factors for adverse events.
Mortality was higher in prosthetic valve IE 42/65 (66.2%) when compared to native 
valve IE
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56/151 (37.0%) (p<0.001). In a multivariate analysis between prosthetic valve IE 
versus native valve IE there was no significant difference in mortality.
Age (per life year) OR = 1.05, 95%, CI: [1.03-1.08] p<0.001
Female Sex OR = 2.35, 95%, CI: [1.29-4.28] p=0.005
Conservative Treatment OR = 3.39, 95%, CI: [1.80-6.38] p<0.001
Table 2. Prognostic Factors Mortality, multivariate analysis
Surgical versus conservative treatment
A total of 38.9% patients were accepted for surgical intervention. Mortality was 
higher in the conservative treatment group (46.9%) when compared to the surgical 
group (19.0%) (p=<0.001). In a multivariate analysis this difference remained 
significant (OR = 3.39, 95% CI: [1.80-6.38] p<0.001) (see table 2).
SA endocarditis or prosthetic valve IE were not independent prognostic factors 
for receiving surgical intervention. Women were less likely to have surgical 
intervention performed (OR=1.96, 95% CI: [1.06-3.61] p=0.031). Also, aging was an 
independent prognostic factor for not receiving surgery in a multivariate analysis 
(annual OR=1.04, 95% CI: [1.02-1.06] p<0.001) see table 3.
The incidence of adverse events was higher in the surgical group (73.8%) than in the 
conservative treatment group (48.4%). Surgical intervention was an independent 
prognostic factor for adverse events (OR=3.03, 95% CI: [1.64-5.55] p<0.001).
Female Sex OR = 1.96, 95%, CI: [1.06-3.61] p=0.031
Age (per life year) OR = 1.04, 95%, CI: [1.02-1.06] p<0.001




To our knowledge this is the first nation-wide research that demonstrates a 
significant increase in the incidence of IE above the historical trend after the 
introduction of the ESC 2009 guidelines (8). Although there has been some 
research on the incidence after the introduction of the revised ESC guidelines, 
mainly in France, this is the first research that focuses on a country as a whole 
and spans a longer period of time (12). Although previous research from Pant et al 
already demonstrated a significant rise in Streptococcus IE incidence this focussed 
on the ACC/AHA IE guidelines. The fact that the same trend is seen after the 2009 
ESC guidelines is a confirmation of Pant et al results as both the ACC/AHA and ESC 
use virtually similar criteria for prophylaxis (5,8,11). As Drayer et al demonstrated 
a similar trend in the UK the evidence seems to be tipping the scale in favour of a 
more strict attitude towards prophylaxis in patients at risk that are currently not 
covered by the IE guideline (10). However, care must be taken when interpreting 
these results. These are trends and not prospective studies. Furthermore, possible 
harm done by the abundant use of antibiotics in prophylaxis must be considered 
when trying to prevent a relatively uncommon disease (eg anaphylaxis, antibiotic 
resistance)
When looking at the temporal relationship between the publication of the ESC 
guideline in august 2009 and the penetration of this guideline within the healthcare 
profession it is important to consider the fact that the National Heart Foundation 
(Nederlandse Hart Stichting) published a wide spread folder in December 2008 
containing the revised criteria for prophylaxis as well as communicated by its 
author in the Nederlands Tijdschrift voor Geneeskunde (17). Therefore at the time 
of official publication of the new endocarditis guideline this was already in wide 
use in the Netherlands (17). 
The significant difference in mean age at time of death before and after the ESC 
guideline introduction could be due to increasing cohort of elderly patients at risk 
for IE. The cohort of the so called baby boom generation is aging and coming in 
the range of patients prone for IE. 
Our study also showed that Staphylococcus Aureus is the single most frequent 
organism. This is probably explained by the fact that the population prone for IE 
is increasing. An aging population with an increase in degenerative heart valve 
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disease, the increased use of prosthetic heart valves and the increased incidence 
of pacemaker devices combined with a better prognosis in patients with congenital 
heart disease makes for a much larger cohort at risk (16). At the same time there 
is a rise in invasive procedures in just this population which is a risk factor for IE. 
As less than one percent of our population had a MRSA cultured this indicates that 
a strict use of antibiotics combined with greater awareness amongst healthcare 
workers may prevent the spread of MRSA in the IE population. 
Before and after the 2009 ESC guideline we see a significant increase in the 
number of streptococci related IE cases. This could reflect the less strict indication 
for prophylaxis as this mainly targets streptococci. The fact that in the patients 
with an identified microorganism entry site the most prevalent entry site was the 
oropharyngic cavity is a worrying finding as this is the main target for antibiotic 
prophylaxis. This is emphasized as one considers that the most prevalent 
Streptococcus is S. Mitis.  Furthermore, the other main entry sites were the 
gastrointestinal and urinary tract and the skin. The former two are affected by the 
prophylaxis guideline as well.
In a small amount of cases no organism was cultured. This may be due to a general 
practitioner staring antibiotics prior to presentation in one of the sample hospitals. 
The mortality due to IE is considerable in our population and higher than in various 
other research (1-4,13). As most research focuses on tertiary centres which have 
a great selection bias this may explain the higher mortality rate in our population. 
Patients no longer eligible for surgical intervention may enter a palliative setting 
and therefore may not be included in studies on IE that most of the time run 
in larger surgical clinics. This may indicate that the advances in survival we have 
made in recent history may be influenced by selection bias. To our knowledge 
this is one of the few studies that focuses on the general population instead 
of selecting patients suitable for surgical intervention as is being done in most 
studies (1,2,4,13). 
The mortality in women is significantly higher than in men and they receive 
less surgical intervention what in itself is a prognostic factor for survival. The 




The difference in moment of increase in incidence between the male and female 
population may be explained by the fact that IE is more often underdiagnosed and 
treated less aggressive in women than in men. A fact that could explain the higher 
female mortality rate as well. Another explanation might be that men, as they 
are obviously more prone to endocarditis may be more susceptible for IE when 
prophylaxis guidelines are less strict. We hypothesise that poorer oral hygiene in 
men combined with less strict prophylaxis has led to the significant increase in just 
this population.  
One third of IE patients has prosthetic valve IE. This reflects the growing incidence 
in the use of prosthetic material in cardiac surgery and will only increase in the 
future. The low incidence in right sided IE is caused by the dwindling number of 
intravenous drug users in the Netherlands (18). This group of patients, historically 
at risk for IE, is getting smaller over the course of time and may disappear 
altogether in the future. 
The mortality in the conservatively treated group of patients is much higher than 
in the surgical group. This reflects a selection bias, those fit for surgery will have a 
better pre-operative condition than those unfit for surgical intervention. A larger 
number of patients will be treated in a palliative setting as they are no longer 
eligible for surgical intervention. As there was no selection bias in our study this 
may explain the high mortality rate in the entire population and even more so in 
the cohort that had a conservative treatment.
LIMITATIONS
There are several limitations to this study. This is a retrospective observational 
study and although we have demonstrated a temporal relation, causality cannot 
be proven. However almost all observational studies with the same study design 
show the same results (10,11).
Furthermore there was no correction for population composition. An ageing 
population is at higher risk for the development of IE. A correction for immigration 
of people from countries with a higher risk of rheumatic heart valve disease was 
also not performed and could influence the results as well. 
Another limitation is the possible small sample size. However, in contrast to 
other studies on the subject we have detailed and verified information on our 
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sample patients and do not depend on discharge information which is subject 
to registration of discharge diagnosis and greatly depends on the physicians will 
to register diagnosis properly. We therefore feel that our sample populations is 
representative for the nation-wide cohort. 
Finally we have no information on the prescription of antibiotics before and 
after the 2009 guideline introduction. However the National Heart Foundation 
(Nederlandse Hart Stichting) has been quite thorough in its education of healthcare 
professionals responsible for the prophylaxis in patients at risk and we expect 
quite rigorous adherence to these guidelines. 
CONCLUSION:
The incidence of IE in the Netherlands is increasing and since the introduction of 
the 2009 ESC guideline the increase of IE projected above the historical trend. IE 
is a dangerous disease with high mortality rates in women and the elderly which 
has hardly changed over the years. S. Aureus remains the single most common 
pathogen whereas Streptococci as a group remain the most common pathogen. 
After the 2009 ESC guideline we see an increase in the number of Streptococci 
related cases of IE. Caution is advised in interpreting these results as this is a 
observational study and prospective data is lacking. In order to settle the debate 
on the relationship between prophylaxis and IE incidence prospective studies 
should be performed in patients at risk. 
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CHAPTER 3B
INCIDENCE OF INFECTIVE VALVE 
ENDOCARDITIS AS AFTER 
ANTIBIOTIC PROPHYLAXIS 
GUIDELINES CHANGED - THERE IS 
A CHANGE.
F.S. van den Brink, C. Zivelongi, J.M. ten Berg, 
Ann Cardiothorac Surg 2019. doi: 10.21037/acs.2019.06.05 (Editorial)
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From 2007 to 2009 the guidelines for endocarditis saw a major change in the 
prescription of antibiotic prophylaxes to preventive infective endocarditis in the 
United States of America, continental Europe and the United Kingdom1,2,3. Antibiotic 
prophylaxis became much more strict and only a select group of patients was 
still eligible for prophylaxis1,2,3. There was no evidence that chemo-prophylaxis in 
patients with non congenital, non prosthetic heart valve disease would prevent 
the occurrence of infective endocarditis which still ranks as one of the deadliest 
infectious diseases in the western world. We applauded ourselves that science 
and a lack of evidence of the effectiveness of prophylaxis had prevailed. 
In the years that followed this decision, we saw the incidence of infective 
endocarditis rise. It rose in the USA, in the United Kingdom and in continental 
Europe and in many other places in the world4,5,6,7. We told ourselves it was due to 
an aging population, more invasive medical procedures or a combination of both 
as age and medical treatment are two old friends walking together as risk factors 
for many diseases but especially infective endocarditis. And although some of us 
started suggesting we might be wrong in such a strict use of chemo prophylaxis 
for the prevention of infective endocarditis they were honed at because were was 
the evidence?
The year 2015 arrived and the European Society of Cardiology was preparing 
their new guideline for the diagnosis and treatment of infective endocarditis. 
Some time before the guideline came in to print two studies appeared that did 
show that not only the incidence of infective endocarditis was on the rise but 
that when prophylaxis guidelines became much more strict there was a sudden 
increase above the expected historical trend in Streptococci mediated infective 
endocarditis4,5. And then a strange thing happened. In stead of trying to weighing 
costs and benefits of prophylaxis it was argued that evidence was at best 
circumstantial. More likely it was due to, again, a changing population and health 
care related IE. Not long afterwards a third study confirmed  the results of the 
previous two studies  using more or less the same methodology6. 
And so we have arrived in 2019. Guidelines on chemo–prophylaxis for infective 
endocarditis are just as strict as they were when we designed them between 2007-
20098.  In the meantime we have seen a rise in IE in almost all studies. Several of 
these studies also showed an increase in the streptococci related IE follow the 
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guideline changes4,6. What we have not seen is a decline in IE. We have neither 
seen an improvement in survival of patients suffering from this devastating 
disease. And still, despite an increasing number of studies that show not only an 
increase in IE incidence but also a relation between stricter IE chemo-prophylaxis 
and an increase in preventable IE we still consider the evidence not to be enough 
to change the guideline back to what they were. Another thing that we have 
also not witnessed is patients suffering from chemo–prophylaxis with lethal 
consequence9.  It is safe with very little patient harm or discomfort and is applied 
in many medical settings often with very little evidence to back it up. In fact, the 
evidence in the case of IE is actually quite strong when comparing it to other uses 
of chemo–prophylaxis. 
In short, we do very little harm in giving patients chemo–prophylaxis and we 
probably do a lot of good in giving patients chemo–prophylaxis to prevent IE from 
rearing it’s ugly head. 
We should therefore be brave and admit that we might have been wrong. We 
should reinstate chemo–prophylaxis for all patients with valvular anomalies to 
prevent IE from affecting these patients at risk. We should make all possible effort 
to prevent this disease from happening because we have great difficulty in treating 
it and the toll that patients have to pay is high. 
Yes, not all evidence points in the direction of a beneficial effect of chemo–
prophylaxis but a lot does. Very little evidence points in the direction of a detrimental 
effect of chemo–prophylaxis on patient care. We have a rare opportunity to 
conduct an almost world wide study in reinstating the chemo–prophylaxis as it 
was before 2007 and then see what happens to the incidence if IE. In doing so we 
can make a major step forward and hopefully settle an already very long debate. 
And in this way also halt an even further increase in infective endocarditis. 
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Treatment of pacemaker (PM) device infections is challenging in pacemaker 
dependent patients. We propose a novel implantation strategy for this group of 
patients. 
Methods
Patients who were PM dependent and were admitted with a PM infection received 
a combined procedure of LV epicardial implantation of a PM lead and subsequent 
extraction of the infected system. No temporary pacing wire was used and the PM 
generator was placed in the left flank.
Results
 Between 2012 and 2015 we treated 16 patients who were PM dependent with a 
PM infection. The majority of patients was male (81% (13/16)). The median age was 
71 years (50-91). The cause of infection was valvular endocarditis in 38% (6/16), 
lead infection in 25% (4/16) and isolated pocket infection in 38% (6/16). 
All patients underwent epicardial implantation of a LV lead (St Jude 1084T bipolar 
lead) and extraction of the infected device. There was no peri-procedural mortality 
and no-post procedural tamponades occurred. There was one complication in the 
form of a haemorrhage at the infected device extraction site. In the median follow 
up period of 17 months there were  4/16 deaths, none of which were attributable 
to epicardial LV implantation. LV lead thresholds were 1.1V (+/- 0.7V) upon 
implantation which increased to 1.2V (+/- 0.6V) at 0.4ms pulse duration. There 
were no re-infections of the epicardial lead or device.
Conclusion
Epicardial left ventricle pacemaker implantation and subsequent extraction of an 
infected pacemaker in pacemaker dependent patients is  feasible and safe with 
good long term outcome.
Keywords:  Pacing, Infection, Extraction




As the use of Cardiac Implantable Electronic Devices (CIED) is increasing, so is 
the risk of device infection 1,2. Not only are CIED’s used more often, the patients 
undergoing implantation live longer and leads remain longer in situ 3.  CIED 
infections are a significant cause of morbidity and mortality through a mechanism 
of systemic infection and the need for extraction of the device including intra-
cardiac leads. Although treatment of CIED infection is well established, the timing 
of re-implantation is based largely on expert opinion 4,5-8. 
Of special consideration are patients who are pacemaker (PM) dependent and 
have a device infection. Although there are established guidelines on how to treat 
CIED infection there is little evidence on extraction and re-implantation timing and 
strategies in PM dependent patients 4, 5. 
In general, three different re-implantation strategies have been described. One 
consists of extraction of the infected device, the subsequent use of a temporary 
pacing lead until the infection has subsided after which a pacemaker can be 
implanted on the contralateral side 9. Another strategy is to implant an epicardial 
right ventricle (RV) lead via a subxiphoid incision 9, 10. These two strategies have 
been compared in which the first strategy leads to prolonged hospitalisation while 
the second leads to higher long term RV-lead thresholds 9, 10. The third strategy is 
applied in case of an isolated pocket infection where during a single procedure 
extraction of the infected device is followed by implantation of an endocardial 
device on the contralateral site 11. 
We describe the use of an alternative fourth strategy in which a permanent left 
ventricular (LV) lead is implanted surgically via mini-thoracotomy and the device 
is placed in the left flank. This avoids the use of a temporary pacing lead which 
poses the possible risk of dislodging, perforating, persistent bacteraemia through 
bacterial colonization and various other complications 12. Moreover it places 
the pacemaker outside of the bloodstream hereby minimising possible risk of 




A prospective in-hospital registry on PM device extraction was kept from 1st January 
2012 onwards in the St. Antonius Hospital in Nieuwegein, the Netherlands, a large 
volume referral centre. All patients undergoing CIED extraction were included in 
this database. For this specific analysis we included all PM dependent patients from 
this database. In 2016 we performed an analysis of all patients. The following data 
was collected: age, sex, PM dependency, reason for extraction (lead dysfunction, 
isolated pocket infection, lead infection, endocarditis), left ventricular ejection 
fraction (LVEF), previous cardiac surgery, in hospital death, 30 day mortality, all-
cause mortality, complications, NYHA class, renal function, diabetes and duration 
of hospital stay 13, 14. Patient data of patients who were transferred to a referral 
hospital were collected by contacting the consultant cardiologist treating that 
patient. 
Pacemaker dependency was defined as more than 95% RV pacing or total 
Atrio-Ventricular heart block 10. Left ventricular function was determined using 
echocardiography  13.  Renal function was determined per the KDOQI Clinical 
Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and 
Stratification 14. A renal function of class 3 and lower (GFR<60) was considered 
impaired renal function. Data are shown as median +/- SD.
PROCEDURAL TECHNIQUE
Lead implantation and subsequent transvenous extraction was performed 
under general anaesthesia and endotracheal intubation with a dual lumen 
tube in the operating theatre. During the entire procedure a cardio-pulmonary 
bypass machine is kept standby in case of possible complications requiring 
urgent surgery. Prior to extraction a Trans Oesophageal Echo was placed in 
the oesophagus in order to monitor cardiac function, pericardial effusion and 
procedural progress of the extraction.  A combined team consisting of a cardio-
thoracic surgeon, electrophysiologist, anaesthetist, clinical perfusionist and PM-
device technician performed the implantation and subsequent extraction. After 
appropriate antibiotic therapy the epicardial lead and device were implanted first. 
This was done to ensure pacing during the procedure. A St Jude Medical Myodex 
® 1084T bipolar lead with screw was used. The PM generator was placed in the 
left axilla or flank unless this was contra-indicated. The implanted PM generator 
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differed per patient and was implanted at the discretion of the attending physician 
in view of possible future upgrade to a DDD-pacemaker, Internal Cardiac 
Defibrillator, Cardiac Resynchronization Therapy (CRT) Defibrillator (CRT-D) or 
Pacing (CRT-P) device. Afterwards extraction of the device and the endovascular 
leads was performed. There was no use of temporary pacing leads. Extraction of 
the endovascular device took place using a stylet, locking stylet, mechanical dilator 




Between January 2012 and December 2015 a total of 129 patients underwent CIED 
extraction. Referred patients made up 62/129 (48%) while the rest of the patients 
had their infected device implanted in the St. Antonius Hospital. Of the total cohort 
of 129 patients 27 patients were pacemaker dependent. Of these 27 patients, 16 
had a form of device related infection. The majority of these patients were male 
13/16 (81%) with a median age of 71 years (50-91) at the time of extraction. Of 
these 16 patients 6 had a previous history of sternotomy: 2 CABG’s and 2 isolated 
valvular surgeries (both aortic valve replacement), one Bentall procedure and one 
surgical repair of an atrial septal defect type 2. Of these 16 patients the infected 
device was a pacemaker in 10 cases (all of which were DDD pacemakers), an ICD 
in 2 cases, a CRT-D in 2 cases and a CRT-P in 2 cases. The indication for pacing was 
total AV-block in all patients. The indication for an ICD was an ejection fraction 
lower than 35% in two patients, a hypertrophic cardiomyopathy in one patient and 
idiopathic ventricular tachycardia in one patient. There were two patients with a 
CRT-P; one patient received a CRT-P after His-ablation and one patients had an 
indication for CRT-D but refused and received CRT-P only on his own request (see 
table 1). Non-cardiac previous medical history was present with respect to DM in 4 
patients and with respect to impaired renal function in 11 patients. Left ventricular 
function was normal (>55%) in 4 patients, slightly impaired (45-54%) in 4 patients, 
impaired (30-44%) in 4 patients and severely impaired (<30%) in 4 patients as well. 
Half of the patients were NYHA class 1, 5/16 patients had NYHA class 3 and 3/16 




Of the population of CIED infected patients 6/16 patients had valvular endocarditis, 
4/16 patients had a lead infection and 6/16 patients had an isolated pocket infection. 
Cultures were positive with a single organism in 14/16 patients. One patient had 
multiple organisms cultured making the identification of a single pathogen difficult 
(patient 6) and one patient had a negative culture after antibiotic treatment by a 
referring physician. Most cultures were positive with commensal bacteria of the 
skin: 6/14 S Aureus, 2/14 S. Epidermis, 2/14 Propionibacterium Acnes, 1/14 S. 
Hominis, 1/14 S. Schleiferi and two miscellaneous bacteria (a Serratia Marcescens 
and a Kleibsiella Oxytoca) . There were no Methicillin-resistant Staphylococcus 
aureus (MRSA) cultured. (see table 1)
Extraction
Re-implantation was performed prior to transvenous extraction by placing an 
epicardial left ventricle lead in all 16 patients. Of these 16 patients 13/16 received 
epicardial implantation alone.  In 2/16 patients an initial procedure with epicardial 
LV lead implantation and subsequent extraction was performed after which, in a 
second procedure, an endovascular lead was implanted in a later stage (patients 
nr. 15&16). One patient was implanted with an endovascular system at a later 
stage when the infection was subdued after which the epicardial lead was left in 
situ but was no longer functional  (patient nr. 7). Complete extraction of the CIED 
was achieved in 13/16 patients. The other three patients had remaining leads or 
part of it in situ. 
Outcome
Of the 16 patients receiving epicardial lead implantation none died during 
implantation and subsequent extraction. All-cause mortality was 25% (4/16) 
during follow up. 
One patient died during hospitalisation due to progressive heart failure. This 
patient was a non-responder to CRT-P and did not die due to CRT-P downgrade. 
This patients refused CRT-D therapy and was known to have end-stage heart 
failure. He was planned for CRT-P re-implantation but died of aforementioned end 
stage heart failure before this could be achieved. The epicardial system however 
did not get infected within this period and assured adequate LV-pacing.
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The other three patients died of natural cause more than 6 months after follow 
up. In all cases, there was no known relation to the pacemaker system. There was 
only one complication during the operative procedure in which a haemorrhage 
occurred on the extraction site at the subclavian vein. Four other patients had 
complications during hospitalisation: two patients developed heart failure, one 
patient developed an inflammatory response with a Systemic Inflammatory 
Response Syndrome (SIRS) but none of these were attributed due to PM device 
extraction by the treating physician. There were no complications directly 
attributable to the implantation of the epicardial PM system including tamponade.
PM-related outcome
Median follow up was 17 months (+/- 11.5 months). A total of 10/16 patients had 
a follow up of at least a year. Median duration of hospital stay was 22 days (+/- 37 
days). The initial threshold of the LV lead upon implantation was 1.1V (+/- 0.7V) at 
0.4ms pulse duration which increased to 1.2V (+/- 0.6V) at 0.4ms pulse duration 
at the last recorded LV threshold which was not significant (p=0.63) (see table 2). 
Three patients were lost to follow-up with respect to the LV lead threshold; two died 
before a LV threshold could be determined and one patient received an upgrade 
to a complete endovascular system before a LV threshold could be determined. 
None of the patients developed re-infection of the implanted LV endocardial lead 
or device after implantation. None of the patients who were downgraded from a 
dual chamber pacemaker to a VVI system developed clinical signs of a pacemaker 
syndrome due to permanent VVI LV pacing (see table 2). Furthermore, all patients 
who initially had an ICD (patients nr. 7&16) as well as the patient that had an CRT-D 
(patient nr. 15) received an upgrade to either a combined endovascular-epicardial 
system (patients nr. 15&16) or a complete endovascular system (patient nr. 7). 
The other patient who received a VVI system died before an upgrade was possible 
(patient nr. 1). 
DISCUSSION
CIED related infections are becoming increasingly common as the use of CIED’s is 
growing in an aging population with an increased life expectancy 1-3, 6, 7, 15, 16.  This 
problem will only increase in the future.
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We describe a strategy of implantation of a new pacemaker with an epicardial LV 
lead and subsequent extraction of the infected device in one surgical procedure, 
which to our knowledge has not been described before. The technique described 
has several benefits. First of all the proposed implantation-extraction strategy 
places the epicardial lead and pacemaker device outside of the bloodstream 
minimising the risk of recurrent or persistent systemic infection. Second there is no 
need for trans-venous (temporary) pacing leads. This minimizes the risk of possible 
tamponade which is reflected by our results showing the absence of tamponade as 
a procedural complication. These are common complications of using temporary 
pacing leads and in turn the use of temporary pacing wires is associated with a 
high complication rate in general exceeding 30% 12. In all, especially in pacemaker 
dependant patients this technique is well fitted to ensure continuous pacing 
during extraction. Combining two procedures may also reduce the risk of two 
separate procedures and increases patient comfort. As patients are under total 
anaesthesia patient discomfort is minimal. There is little evidence on timing and 
location of pacemaker implantation in PM dependent patients. The evidence 
in the guidelines is based on expert opinion. Recently Amraoui et al as well as 
Mountantonakis et al have described new techniques that show promising results 
9-11. Although Amraoui and his group described a somewhat similar technique, 
with a subxyphoidal approach of the RV, they observed a higher complication rate 
mainly driven by cardiac tamponade 9, 10. Using a screw-in epicardial lead on the 
thicker LV wall, the risk of tamponade is reduced. As the results of the current 
study show no major complication of the epicardial implantation, the combined 
approach could be considered safe. In three of the patients a lead or part of a lead 
remained in situ. However this did not lead to infection of the epicardal system. 
This underlines the safety of this procedure from an infectious point of view. 
The patient population in this study is diverse. The reason for extraction ranges 
from isolated pocket infection to full blown endocarditis. CIED vary amongst 
patients from single chamber pacemakers to CRT-D devices. The number of leads 
varies as well between the various forms of CIED. Furthermore patients varied in 
respect to previous medical history, presence of ischaemic heart disease, previous 
sternotomy, NYHA class, presence of diabetes, renal function and complete 
extraction of the CIED. However, we believe this reflects a real life setting and 
makes the feasibility of the described treatment strategy applicable to a wide 
variety of patients with different types of CIED infection. 
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The use of VVI pacing has not led to impaired left ventricular function in this 
population illustrating the feasibility of left ventricular pacing in pacemaker 
dependent patients. Patients who were in need of a CRT-D or ICD system received 
such a system in a later stage. Therefore this implantation strategy can be used in 
patients with either DDD, VVI, ICD and CRT-D systems.
A quarter of the patients in this study died. We must however state that none of 
the deaths was directly contributed to the described technique. A large portion of 
the patients suffered from infective endocarditis of which mortality ranges from 
30-60% 17, 18. Also three patients died of natural causes at home of which two were 
over 80 years old which is a normal life expectancy in the Netherlands. One patient 
developed a SIRS reaction.  This has been previously described with extraction of 
infected CIEDs and in this case was not thought secondary to re-implantation. 
The duration of hospitalization also varies greatly between patients. The relatively 
long mean hospital stay is mainly driven by three patients who were hospitalized 
for a total of 307 days because of valvular endocarditis with a need for long-
term antibiotic treatment and postoperative complications, none attributable 
to the lead implantation and subsequent transvenous leadextraction. Of the 
entire cohort only 4 patients were hospitalized longer than 35 days; the three 
aforementioned patients and one patient who was hospitalized for 36 days. This 
makes the average length of stay shorter when considering hospitalization due to 
extraction and re-implantation alone. 
The microbiological findings reflect the commensal flora of the human skin 
as largest source of infection. This is similar to those findings in other studies 
describing CIED infections 9-11, 16. S. Aureus is the most common pathogen. 
We did not find any MRSA. This largely reflects the strict use of antibiotics in 
the Netherlands which has led to relatively low MRSA rates 19. All pathogens 
were treated after consulting a microbiologist according to the local in hospital 
guidelines. Complete extraction was not achieved in all patients. However, this did 
not account for any re-infections. The absence of re-infection suggest a benefit 
from the use of organism directed therapy as well as the safety of the procedure. 
The LV threshold did not increase significantly during a median follow up of 18 
months. As the increase in thresholds of epicardial leads is mostly seen in the first 
30 days to six months after implantation, this trend should be representative of 
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long term lead behaviour. In none of the patients did thresholds exceed acceptable 
values needing re-intervention. These results are consistent with current literature. 
In comparison Koos et al report an increase in threshold in the first 6 months in 
both groups, whereas Mair et al and Buiten et al report of a stable epicardial lead 
threshold over up to 30 months of follow up 20-22. Garikipati et al report significantly 
higher thresholds in the epicardial leads as compared to transvenous LV leads 23. 
In three patients there was a loss of follow up concerning the LV-lead threshold 
and are therefore not included in the last available LV threshold. 
LIMITATIONS
This is a retrospective analysis of a case series and therefore subject to limitations 
associated with this type of research. Furthermore our patient population is quite 
heterogeneous with a variety of co-morbidities as well as implanted devices. 
On the other hand it does show that this technique is feasible in a wide variety 
of patients. In addition the size of our population is relatively small making any 
sound statistical conclusion very difficult. Further research is needed to evaluate 
this technique in larger patient groups, ideally in a randomised controlled trial 
versus other implantation and extraction strategies. The follow up period in this 
study is 18 months. To make any statements on the long term outcome of LV 
epicardial implantation in pacemaker device infection in pacemaker dependent 
patients a  longer follow up is needed. 
CONCLUSION
In this single centre observational study left ventricular epicardial implantation of 
a pacemaker and subsequent transvenous extraction of the infected device and 
leads in pacemaker dependent patients is a safe surgical procedure. There were no 
complications due to implantation and only one due to extraction. LV thresholds 
did not increase after implantation and no re-infections were observed. 
LV epicardial implantation is a safe and feasible procedure in pacemaker 
dependent patients with an infected CIED.  
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INCIDENCE AND OUTCOME OF 
PROSTHETIC VALVE ENDOCARDITIS 
AFTER TRANSCATHETER AORTIC 
VALVE REPLACEMENT IN THE 
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Transcatheter aortic valve replacement (TAVR) is increasingly being used as 
an alternative to conventional surgical valve replacement. Prosthetic valve 
endocarditis (PVE) is a rare but feared complication after TAVR, with reported first-
year incidences varying from 0.57% to 3.1%. This study was performed to gain 
insight into the incidence and outcome of PVE after TAVR in the Netherlands.
Methods 
A multicentre retrospective registry study was performed. All patients who 
underwent TAVR in the period 2010-2017 were screened for the diagnosis of 
infective endocarditis in the insurance database and checked for the presence of 
PVE before analysis of general characteristics, PVE parameters and outcome.
Results 
A total of 3968 patients who underwent TAVR were screened for PVE. During a 
median follow-up of 33.5 months [interquartile range (IQR) 22.8-45.8], 16 patients 
suffered from PVE (0.4%), with a median time to onset of 177 days (IQR 67.8-
721.3). First-year incidence was 0.24% and the overall incidence rate was 0.14 
events per 1000 person-years. Overall mortality during follow-up in our study was 
31%, of which 25% occurred in hospital. All patients were treated conservatively 
with intravenous antibiotics alone, and none underwent a re-intervention. Other 
complications of PVE occurred in 5 patients (31%) and included aortic abscess (2), 
decompensated heart failure (2) and cerebral embolisation (1).
Conclusion 
PVE in patients receiving TAVR is a relatively rare complication and has a high 
mortality rate.
Keywords: Structural heart valve disease · Structural heart intervention · Trans-
catheter aortic valve replacement · Aortic valve stenosis · Prosthetic valve 
endocarditis




Trans-catheter aortic valve replacement (TAVR) is increasingly being used as 
an alternative treatment to conventional surgery in patients with severe aortic 
stenosis who are considered to be inoperable or at high or intermediate surgical 
risk, recently even with beneficial results in low-risk patients [1–5]. One of the 
most feared complications after TAVR or surgical valve implantation is prosthetic 
valve endocarditis (PVE) [6, 7]. Known risk factors for PVE are advanced age, 
renal impairment, diabetes mellitus, chronic obstructive pulmonary disease 
(COPD) and residual aortic regurgitation following valve surgery [8, 9]. PVE is a 
rare complication, with reported first-year incidences of 0.3%-1.8% after surgical 
aortic valve implantation (SAVR) [2, 6, 10–13], associated with high morbidity and 
mortality rates [10, 13]. For TAVR these incidences vary from 0.57% to 3.1%, based 
on small studies and a few larger nationwide registries [9, 13–17]. With the shift 
of TAVR indication towards lower-risk patients, it is of particularly interest how the 
incidence and outcome of PVE post-TAVR differs from post-SAVR. This research 
was performed to gain insight into the incidence and outcome of PVE after TAVR 
in the Netherlands.
MATERIALS AND METHODS
A multicentre retrospective registry study was performed in eight centres in the 
Netherlands performing TAVR, including all patients who underwent TAVR in these 
centres in the period 2009-2017. Data were extracted using the in-hospital TAVR 
registry of each participating centre.
The national insurance database (Diagnose Behandel Combinatie) was screened for 
the diagnosis of infective endocarditis (IE) in all post-TAVR patients. This database 
registers all ambulatory diagnoses and hospital admissions with main discharge 
diagnoses (primary and secondary) according to the International Statistical 
Classification of Disease and Related Health Problems (ICD-10). Every patient in 
the Netherlands has a unique patient identification number, which can be used 
for screening diagnoses in the insurance database. Patient identification numbers 
of all TAVR patients were screened for IE as primary or secondary diagnosis in the 
insurance database, using the IE-specific ICD-10 codes I33.0, I33.9, I38 and I39. 
Patients assigned one of the mentioned ICD-10 codes after the TAVR procedure, 
who were in hospital >1 week or who died before discharge were suspected of 
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having IE. The data of these patients were checked for correctness of the diagnosis 
of IE, using the modified Duke Criteria [18, 19]. Patients with possible or definite 
IE, based on the modified Duke Criteria, were screened for the presence of PVE 
using patient records.
Patients with PVE were analysed for age, gender, valve type and size, date of PVE 
diagnosis, organism, concomitant IE of a non-TAVR valve, presence of a cardiac 
implantable electronic device (CIED), concomitant IE of a CIED, re-intervention 
(i.e. re-TAVR, conventional surgery, conservative treatment with antibiotics or 
palliative care), mortality and complications according to the Valve Academic 
Research Consortium (VARC-2) [20]. Baseline characteristics of patients with PVE 
were compared with those of patients without PVE. A sample population of 848 
patients without PVE and with complete baseline and hospitalisation data during 
transcatheter aortic valve implantation was used as a control group (confidence 
level of 95% with a confidence interval of 1.03, which represents a margin of error 
of 3%).
Complications of PVE were defined as cerebral embolisation of a vegetation, 
embolisation of a vegetation elsewhere, development of total atrioventricular (AV) 
block, root abscess, valve destruction with severe aortic regurgitation (AR) and 
decompensated heart failure due to AR. Investigators had the possibility to add 
free text remarks to the database to specify certain aspects that were not covered 
by the database. Left ventricular function was determined using echocardiography 
[21]. Renal function was determined per the KDOQI (Clinical Practice Guidelines 
for Chronic Kidney Disease: Evaluation, Classification, and Stratification) [22]). 
A renal function of class 3 and lower [glomerular filtration rate (GFR) <45] was 
considered to be impaired renal function. Data are shown as median ± standard 
deviation (SD).
Normally distributed variables are reported as mean ± standard deviation (SD) and 
tested with the Student’s t-test. Non-normally distributed variables are presented 
as median (interquartile range, IQR), and the Mann-Whitney U test was used to 
test for significant differences. Frequencies and percentages were calculated 
and used to express categorical variables. For distribution analysis of categorical 
variables, the chi-square test was used. Statistical analysis was performed using 
SPSS version 25 (IBM Corp., Armonk, NY, USA).





A total of 3968 patients who underwent TAVR between 2009 and 2017 were 
included in the study and screened for PVE post-TAVR. The median follow-up 
period was 33.5 months (IQR 22.8-45.8). Of the 3968 screened patients, 16 (0.4%) 
developed an episode of PVE with an incidence rate of 0.14 event per 1000 person-
years. The median time to onset of PVE was 177 days (IQR 67.8-721.3). In 9 patients 
PVE occurred within the 1st year after TAVR (early PVE) (incidence of 0.23%) and in 
7 patients (0.18%) after 1 year (late PVE).
Baseline characteristics of the PVE and control groups are shown in Table 1. 
Median age was 81.5 (IQR 68-86) years and just over half of the patients were male 
(56%) in the PVE group versus 82.1 (IQR 77-86) years and 46% in the control group. 
Besides impaired renal function, baseline characteristics were not significantly 
different between the two groups. In the PVE group, a history of diabetes was 
observed in 5 of 16 (31%) patients, hypertension in 7 of 16 (44%) patients and 
impaired renal function (GFR <45 ml/min) was present in 12 of 16 (75%) patients, 
which differed significantly from the control group (39 ml/min, IQR 29-57 vs 59 ml/
min, IQR 64-83, p=0.002). None of the patients who presented with PVE after TAVR 
had suffered from IE prior to TAVR. Left ventricular function prior to TAVR was 
good (left ventricular ejection fraction >55%) in 56% (9/12), moderately impaired 
in 31% (5/16) and severely impaired in 13% (2/16). The affected prosthetic valves 
were a CoreValve CRS (Medtronic Inc., Minneapolis, MN, USA) in 25% (4/16), a 
Sapien XT (Edwards Lifesciences LLC, Irvine, CA, USA) in 44% (7/16), an Evolut R 
(Medtronic Inc.) in 13% (2/16) and a Direct Flow (Direct Flow Medical Inc., Santa 
Rosa, CA, USA) in 19% (3/16). The approach to implantation was transfemoral in 
81% (13/16), trans-subclavian in 13% (2/16) and transapical in 6% (1/16). The mean 









Age (years), median (IQR) 81.5 (68-86) 82.1 (77-86) 0.317
Male 9 (56%) 387 (46%) 0.394
Length (cm) 169 (158-180) 168 (161-175) 0.834
Weight (kg) 78 (60-97) 73 (64-83) 0.593
Renal function (eGFR, ml/min) 39 (29-57) 59 (64-83) 0.002
Impaired renal function 12 (75%) 434 (51%) 0.058
Hypertension 7 (44%) 535 (63%) 0.116
Diabetes mellitus 5 (31%) 200 (24%) 0.472
History of endocarditis 0 2 (0.2%) 0.846
TAVR prosthesis
First generation CoreValve 4 (25%) 336 (40%)
Evolut R 2 (13%) 67 (8%)
Sapien XT 7 (44%) 216 (25%)
Sapien 3 0 26 (3%)
Engager 0 18 (2%)
Direct Flow 3 (19%) 23 (3%)
Lotus Valve 0 101 (12%)
Jena Valve 0 63 (7%)
Left ventricular ejection fraction 0.709
Good (>55%) 9 (56%) 560 (66%)
Moderate (35-55%) 5 (31%) 216 (25%)
Poor (<35%) 2 (13%) 74 (9%)
Table 1 Baseline characteristics
aThis is a selected sample population consisting of patients without PVE after TAVR  
EF ejection fraction, eGFR estimated glomerular filtration rate, PVE prosthetic valve 
endocarditis, TAVR transcatheter aortic valve replacement
All patients had positive blood cultures, of which the most prevalent pathogen was 
Enterococcus faecalis (5/16). The other pathogens were Staphylococcus aureus (4/16), 
Streptococcus mitis (3/16), Klebsiella oxytoca, Pseudomonas aeruginosa, Streptococcus 
gallolyticus and a diphtheroid rod which was not defined in more detail. A possible 
entry point for bacteria was found in 9 patients: a gastro-intestinal (GI) entry point 
in 5 (4 GI tract and 1 oral entry point), an infected knee prosthesis, a femoral access 
site, a subclavian access site, and an inguinal abscess of the ipsilateral primary 
access site which developed 1 month after TAVR. Microbiological characteristics 
including entry point and antibiotic treatment of all patients are shown in Table 2.
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Subclavian artery Augmentin, gentamicin and after 
5 days flucloxacillin




Unknown Rifampicin, vancomycin 42
3 Enterococcus 
faecalis
Unknown Amoxicillin and ceftriaxone 42




















Gastro-intestinal Penicillin, gentamicin 42
9 Staphylococcus 
aureus
Unknown Flucloxacillin, gentamicin, 
rifampicin









Unknown Gentamicin, penicillin, vanco-
mycin
42













Table 2 Microbiological findings and treatment in the 16 patients who developed PVE after 
TAVR. TAVR transcatheter aortic valve replacement
Outcomes
Outcomes of the patients with PVE after TAVR are shown in Table 3. The mean 
(±SD) length of hospitalisation was 31.2±14.6 days. In the median follow-up period, 
mortality was 31% (5/16); 4 patients (25%) died in hospital after the diagnosis of 
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PVE. Three of the nine (33%) patients with early PVE died compared with 2 of 7 
(29%) in the group with late PVE.
Concomitant mitral valve endocarditis was present in 25% (4/16) of patients. Of 
the 4 patients who developed concomitant mitral valve endocarditis 2 (50%) died. 
None of the patients with a pacemaker in situ developed a device-related infection.
Complications of PVE occurred in 31% (5/16) of the patients and consisted of 
cerebral infarction due to embolization of vegetation in 1 patient, aortic root 
abscess in 2patients and decompensated heart failure in 2 patients. Moderate 
aortic valve regurgitation developed in 50% (8/16) of the patients. The initial 
treatment of choice was conservative, i.e. antibiotics alone in 88% (14/16) of 
patients, 2 of 16 patients entering a palliative care setting directly after the PVE 
diagnosis and 1 patient entering a palliative care setting shortly after starting 
antibiotic treatment. All antibiotic treatment was initiated after consultation with 
the attending microbiologist. None of the patients underwent a re-intervention of 
the TAVR prosthesis. Two patients died before assessment of aortic regurgitation 
could be performed.
Outcome n=16
Mortality during follow-up 5 (31%)
In-hospital mortality after diagnosis of PVE 4 (25%)
Cerebral embolisation 1 (6%)
Aortic root abscess 2 (13%)
Decompensated heart failure 2 (13%)
None 11 (69%)
Infected pacemaker 0
Concomitant mitral valve endocarditis 4 (25%)
Time to IE (days) 177 (IQR 67.8-721.3)
Patients with IE within 1 year of TAVR 9 (56%)
Mean (±SD) length of hospitalisation (days) 31.2±14.6
Table 3 Outcomes in the 16 patients who developed PVE after TAVR. PVE prosthetic valve 
endocarditis, IE infective endocarditis, IQR interquartile range, TAVR transcatheter aortic 
valve replacement




This study investigated the incidence and outcomes in patients with an episode 
of PVE after TAVR in the Netherlands. We found an overall incidence of 0.4% 
(incidence rate of 0.13 event per 1000 person-years) with a higher incidence of 
early PVE after TAVR compared with late-onset PVE (0.23% vs 0.18%). In-hospital 
mortality in these patients was 25% and overall mortality 31%.
Several other studies have investigated the incidence of PVE post-TAVR, with 
conflicting results and reported first-year incidences varying from 0.57% to 
3.1% [2, 9, 13–17]. When comparing our results with those of previous studies, 
especially other nationwide registries, we observed lower incidences (cumulative 
and incidence rate). In the studies of Bjursten et al. (Sweden) [17] and Butt et al. 
(Denmark) [13], post-TAVR patients were screened in a similar way to the procedure 
in our study. Both reported higher cumulative first-year incidences (1.4% [17] and 
2.3% [13] vs 0.23% in our study), while incidence rates were more comparable (0.16 
versus 0.13 events per 1000 person-years [13]). This discrepancy in incidence can 
be explained by the different definitions of IE used across these studies. In some 
studies, only cases of PVE or definite IE, as defined by the modified Duke criteria, 
were included, whereas other studies also include possible IE or all patients with 
IE. We examined only patients with PVE, resulting in a lower incidence as compared 
to that in other studies using other definitions. Other possible explanations could 
be a difference in predisposing factors and risk profiles or the small number of 
patients in most studies.
With the ongoing shift in TAVR indication from high-risk towards intermediate- to 
low-risk patients, the comparison between PVE after SAVR versus TAVR becomes 
even more interesting. Reported incidences of PVE post-SAVR are low and 
comparable to those after TAVR, with incidences varying from 0.3% to 1.8% per 
year [2, 6, 11–13], while bioprosthetic surgical valves were more prone to PVE than 
their mechanical equivalents [12].
PVE has been associated with a grave outcome and high mortality rates. In-
hospital mortality rates reported from previous studies ranged from 11% to even 
67% [13, 15, 17, 23–25]. In our study, we observed an in-hospital mortality rate of 
25%. In contrast with these findings, SAVR patients who develop PVE seem to have 
better outcomes, with reported in-hospital mortality rates of 14-25% [10, 13]. The 
Chapter 5
76
more advanced age, frailty and presence of more comorbidities in TAVR patients 
compared with SAVR patients could explain this difference in mortality.
All patients who developed PVE following TAVR were treated conservatively 
with antibiotics, and even after prolonged antibiotic treatment the attending 
physicians did not consider any surgical re-intervention (SAVR or re-TAVR). Even 
patients having a Staphylococcus aureus PVE (25%), known for its high complication 
rate, did not undergo re-intervention. This finding may be explained by the high 
to prohibitive surgical risk of this frail patient population added to the surgical 
difficulties of transcatheter aortic valve explantation. Re-intervention in patients 
with PVE after TAVR has been reported previously. However, it was still associated 
with high in-hospital mortality rates [9]. The number of re-interventions in patients 
with PVE after TAVR will probably rise in the future, due to the shift towards 
younger and lower-risk patients with fewer co-morbidities. The role of valve-in-
valve TAVR in patients with PVE is still unclear, and future research investigating 
the feasibility and safety of valve-in-valve TAVR in treating PVE is necessary.
There were differences in baseline characteristics (i.e. more frequent impaired 
renal function in the PVE group) between the two groups. We were, however, 
unable to test for independent risk factors, due to the low number of patients with 
PVE. On the other hand, renal impairment was previously described as a risk factor 
for PVE post-TAVR [9, 17]. Other identified risk factors include older age, male sex, 
diabetes, COPD, vascular complications and residual aortic regurgitation post-
TAVR [9]. PVE was more often observed in patients with a first-generation TAVR 
valve (i.e. Sapien XT, Direct Flow and CoreValve), compared to newer-generation 
TAVR devices. The use of the newer-generation devices has reduced procedural 
complications such as residual aortic regurgitation and vascular complications, 
which may have resulted in a lower risk of PVE. However, more data on the 
incidence of PVE related to device type are necessary.
The most frequent entry point for bacteria was the GI tract, but second came the 
TAVR access site, with one patient developing PVE just weeks post-TAVR. Thus, 
despite TAVR being a minimally invasive procedure, there is still a chance of it 
being the source of potentially life-threatening infections. A temporary pacing 
lead may also be an entry point for bacteria into the bloodstream. Staphylococcus 
aureus was the cause of PVE in 25% of the patients, which was comparable with 
the findings of other studies [17, 23].




This is a retrospective study with inherent limitations. The number of patients with 
actual PVE is small, limiting statistical analysis. As this study relies on an insurance 
database for identification of patients with IE it depends on correct registration 
of these data. It is possible that patients were missed due to inappropriate code 
registration on hospital admission. The relatively short follow-up of this patient 
population who developed PVE after TAVR in this study makes it difficult to draw 
any conclusions on long-term outcome. PVE is a rare disease, making prospective 
research very difficult. We therefore have to rely on data from retrospective 
studies for diagnosis, treatment and prognosis of this often-lethal disease.
CONCLUSION
This was the first study investigating the incidence of PVE after TAVR in the 
Netherlands. The incidence of PVE after TAVR was low, but it had a grave outcome 
with a high mortality rate.
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Surgery for Infective Endocarditis (IE) imposes great challenges in post-operative 
circulatory and pulmonary support but the role of Veno-Arterial Extra-Corporal 
Membrane Oxygenation (VA ECMO) in this respect is unclear.
Methods 
All patients undergoing VA-ECMO after IE surgery were analysed for age, gender, 
medical history, microorganisms, clinical outcome, complications and surgical 
procedure. 
Results
Between 2012 and 2016, 13 patients received VA-ECMO following IE surgery. The 
median age was 62 years (33-73) and 8/13 were male. Previous cardiac surgery 
was present in 9 patients. Surgery for infective endocarditis consisted of a Bentall 
procedure in 10 patients, 2 of which received concomitant mitral valve surgery and 
2 received concomitant CABG. Valvular surgery alone was performed in 3 patients. 
Mortality on VA-ECMO was 62% (8/13). Mortality during ICU stay was 77% (10/13). 
Survival to discharge was 23% (3/13). One patient reached the one year survival 
point. Two patients who survived to discharge have not yet reached the one year 
survival point. Patient related complications occurred in 54% (7/13) of patients 
and consisted of haemorrhage at the cannula site in 4 patients, leg ischaemia in 1 
patient, haemorrhage at another site in 1 patient and infection of the cannula in 
1 patient. ECMO hardware related complications occurred in 1 case consisting of 
clot formation in the oxygenator. 
Conclusion 
VA-ECMO in post-cardiotomy patients who were operated on for infective 
endocarditis is feasible but outcome is poor.
Key words: VA-ECMO, Infective endocarditis, Surgery




Infective endocarditis (IE) is one of the most lethal infectious diseases in the 
western world with mortality rates ranging from 20% to 60% depending on patient 
characteristics, affected valves and organisms involved (1-6). The incidence of IE 
is on the rise (7-9). More and more patients contract this disease due to a change 
in the use of antibiotic prophylaxis, aging population, increase in prosthetic valve 
implantation and increase in invasive medical procedures such as haemodialysis 
(7,8,10-12). Treatment is often difficult and long. Antibiotic courses of up to six 
weeks in combination with possible surgical intervention are the cornerstones of 
IE treatment (12). Surgical intervention will be the treatment of choice in about 
one-third of the patients with IE (2,6). Surgery for IE is often difficult with great 
challenges in post-operative circulatory and pulmonary support, especially in 
those patients who have a history of cardiac surgery in the form of prosthetic 
valve implantation or concomitant or isolated aortic surgery.  
Since the mid 1990’s veno-arterial extra-corporal membrane Oxygenation (VA 
ECMO) has been recognised as a possible life saving technique in the treatment of 
cardiac failure in post-cardiotomy patients (13). It’s use is increasing in the adult 
population and has proven successful in the treatment of cardiogenic shock due 
to, for example, ST-elevation myocardial infarction (14). However there are no 
well established guidelines for the indication of VA-ECMO post-cardiotomy (13). 
Literature suggests that about one third of the patients with cardiac failure post 
cardiotomy may benefit from VA-ECMO treatment (13). When considering VA-
ECMO post-cardiotomy for patients who were operated on for IE there is only 
anecdotal data on the subject but no larger case series exist (15-17). The purpose 
of this study is to present a larger cohort of patients who underwent cardiac 
surgery for IE and received subsequent VA-ECMO treatment as data in this field is 
virtually non-existent. It could provide a proof of concept on the subject and may 
be the starting point for future research and could help in establishing guidelines 
for the indication for VA-ECMO support in post-cardiotomy patients. The aim of 
this study was to gain insight in outcome of patients undergoing surgery for IE and 




An in-hospital registry was kept between 2009 and 2016 on all patients receiving 
VA ECMO for circulatory support in the St. Antonius Hospital, Nieuwegein, the 
Netherlands, a larger tertiary referral centre. ECMO was introduced in 2009. 
The following data were collected: age, sex, medical history including New York 
Heart Association (NYHA)  functional class and left ventricular function, previous 
endocarditis, procedural characteristics including mode of cannulation and 
concomitant use of other circulatory support (e.g. intra-aortic balloon pump (IABP)), 
left ventricular function prior to admission, survival, complications related to the 
patient (e.g. bleeding at the cannula site, limb ischaemia), complications related to 
the ECMO hardware (e.g. pump failure, clot formation), length of ECMO treatment 
and length of stay on the intensive care unit (ICU) and in hospital, haemodynamic 
parameters, C-reactive protein (CRP) as an inflammatory marker mortality and 
neurological outcome. Heart failure was defined according to the NYHA scale.. A 
normal LVEF was defined as more than 50% ejection fraction (EF), a mildly impaired 
LVF was defined as 40-50% EF, a moderately impaired LVF was defined as 30-40% 
EF and severely impaired LVF was defined as an EF of less than 30%.  Neurological 
outcome was defined using the Cerebral Performance Categories Scale (CPC) 
where a CPC score of 1 and 2 was deemed a good neurological outcome (18). The 
Euro-SCORE I was calculated for all patients to assess the chance of peri operative 
mortality.
Statistical analysis was performed using chi-square test for categorical variables 
and Student’s t test for continuous variables when applicable. Continuous variable 
are given as median +/- SD. 
 Although according to Dutch law (Wet Medisch Wetenschappelijk Onderzoek met 
Mensen) there is no need for evaluation by a Medical Ethical Committee (MEC) in 
retrospective cohort research as this is an evaluation by a MEC was performed 
nonetheless in which there was no objection to this study. 
RESULTS
Baseline Characteristics
Between 2009 and 2016 there were 118 patients who were treated with VA-ECMO 
for various reasons such as pulmonary embolism, cardiogenic shock following 
ST-elevation myocardial infarction and post-cardiotomy. In the same period 243 
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patients underwent surgery for IE. Between 2012 and 2016, 13 patients were 
treated with VA-ECMO following surgery for IE. 
Most patients were male (8/13). The median age was 62 years (33-73) with four 
patients being over 70 years old. A medical history concerning cardiac surgery 
was present in nine patients: eight had previous valvular surgery of whom two 
received concomitant coronary bypass surgery graft (CABG) as well, one patient 
had undergone coronary artery bypass graft surgery alone. Aortic surgery prior 
to admission with IE was performed in 54% (7/13) patients all of whom had 
undergone a Bentall procedure. Only one patient had a history of a previous case 
of endocarditis. Functional status was NYHA class 1 in 31% (4/13) of the patients, 
NYHA class 2 in 38% ( 5/13) of the patients and NYHA class 3 in 31% (4/13) of the 
patients. There were no patients in NYHA class 4 or with known end stage heart 
failure. The left ventricular function was good in 31% (4/13), mildly impaired in 
38% (5/13), moderately impaired in 23% (3/13) and severely impaired in 8% (1/13). 
Neurological events in the form of a previous cerebrovascular event was present 
in 31% (4/13) of the patients: There were two patients who had neurological 
impairment prior to surgery both consisting of a CPC score of 3. Of the other 
patients there were two patients with CPC score 2 and nine patients with CPC score 
1. CRP levels prior to surgery were 57.7 (8-169). A history of diabetes was observed 
in 23% (3/13) of the patients, atrial fibrillation in 31% (4/13) of the patients and 
hypertension in 62% (8/13) of the patients. The Euro-SCORE prior to surgery was 
41.7% (12.8%-61.5%) (See table 1: Baseline characteristics)
Baseline Characteristics Number
Male 62% (8/13)
Median Age (years) 62 (33-73)
Previous Endocarditis 8% (1/13)
Previous Bentall 62% (8/13)
Previous CABG 23% (3/13)
Previous CVA/TIA 31% (4/13)
COPD NA
Peripheral Artery Disease 8% (1/13)
Impaired Neurological Function (CPC 3-4) 15% (2/13)
Median EURO-SCORE 41.7% (Range 12.8%-61.5%)
Table 1: Baseline Characteristics
Abbreviations : CABG: Coronary Artery Bypass Graft. CVA: Cerebrovascular Accident. TIA: 





Surgical intervention consisted of a Bentall procedure in 10 patients (77%), two 
of which received concomitant mitral valve surgery and another two received 
concomitant CABG. In total 21 patients received ECMO support after a Bentall 
procedure in our institution of which 10 received it for infective endocarditis. 
Isolated valvular surgery without aortic involvement or concomitant CABG was 
performed in 3 patients: 1 mitral valve replacement, 1 aortic valve replacement and 
1 combined procedure. All patients had positive cultures: Staphylococcus aureus in 
three cases, Enterococcus faecalis in three cases, Enterococcus faecium in two cases, 
Escherichia coli in one case, Staphylococcus epidermis in one case, Streptococcus 
mitis in one case, Haemophilus parainfluenzae in one case and Candida albicans 
in one case. All patients were on maximum inotropic and vasopressor support 
after surgery. In all patients this was done by using noradrenaline and milrinone 
as is customary in our institution. None of the patients were able to wean of ECC 
and all were put on VA-ECMO support post-cardiotomy. The indication for ECMO 
was impossibility to wean from cardiopulmonary bypass following cardiac surgery 
in all patients. None of the patients received concomitant mechanical circulatory 
support by another device than ECMO (e.g.: Intra-Aortic Balloon Pump or Impella 
(Abiomed Europe GmbH, Aachen, Germany). The arterial mode of cannulation 
was in the right subclavian artery in 3/13 patients whereas in the other ten it was 
placed in the femoral artery. 
Outcome
Mortality while on VA-ECMO was 62% (8/13). The cause of death while treated with 
ECMO was severe left ventricular failure in 2/13 patients, severe right ventricular 
failure in 2/13 patients, multi-system organ failure in 3/13 patients and severe brain 
damage in 1/13 patient. Mortality during ICU stay was 77% (10/13) of which one 
patient died due to aspiration pneumonia and one patient was successfully weaned 
from ECMO but had a CPC of 4 which was deemed not recoverable. Survival to the 
ward was 23% (3/13) and all these patients had survival to discharge. One patient 
reached the one year survival point. The other two patients who have survived to 
discharge have not yet reached the one year survival point but are still alive. The 
patients that survived all had good neurological outcome in the form of CPC 1 as 
by clinical observation. Patient related complications occurred in 54% (7/13) of 
the patients and consisted of haemorrhage at the cannula site in four patients, 
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leg ischaemia in one patient, haemorrhage at another site in one patient and 
infection of the cannula in one patient. The ECMO related haemorrhage occurred 
at the subclavian artery in 15% (2/13) and at the femoral artery in 15% (2/13). In 
all cases it was treated conservatively by applying pressure at the cannula site. All 
patients who received femoral cannulation received antegrade leg perfusion as is 
customary in our institution. On patient who developed leg ischaemia underwent 
cannula repositioning which solved this problem. ECMO hardware related 
complications occurred in one case consisting of clot formation in the oxygenator 
possibly due to a strongly elevated platelet count of 657.000mm3 in this patient. 
The oxygenator of this patient was replaced. The median time on VA-ECMO was 5 
(1-15) days, the median time spent on ICU was 6 (2-29) days and the median time 
spent in hospital was 16 (5-78) days. (See table 2: Outcome)
Outcome Number
Mortality on ECMO 62% (8/13)
Mortality on ICU 77% (10/13)
Survival to Discharge 23% (3/13)
Survival >1 Year* 8% (1/13)
All patient related complications 54% (7/13)
ECMO hardware related complications 8% (1/13)
Good Neurological outcome (CPC 1-2) 23% (3/13)
Table 2: Outcome 
Abbreviations: ECMO: Extra Corporal Membrane Oxygenation. ICU: Intensive Care Unit
*Of the three patients that have survived two have not yet reached the one year survival 
point but are alive at the time of the manuscript draft.
When analysing the three patients that survived; they were relatively young with 
a median age of 46 (range 33-51). This is significantly lower than in the group of 
no survivors 66 (range 54-73) p=0.0035. Furthermore valvular surgery only was 
performed in 2/3 surviving patients. 
DISCUSSION:
This study shows that VA-ECMO in patients with cardiac failure post-cardiotomy 
following IE surgery is feasible but has a high mortality rate. To our knowledge this 
is the first case series published on this matter with a larger number of patients. 
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A large portion of the patients described in this study are patients who underwent 
previous aortic surgery. This could complicate surgery through a mechanism 
of altered anatomy making surgery for IE difficult. Previous cardiac surgery can 
impair left ventricular function which can greatly hamper cardiac recovery after 
redo surgical intervention and regain enough cardiac output to be weaned 
of mechanical support post-surgery. A somewhat similar mechanism may be 
the active inflammation and immune response of the patients with infective 
endocarditis. Active infection can impair cardiac function, again, making it difficult 
to come off mechanical support post-surgery.
The surgical procedure that was performed consisted of a Bentall procedure in 
more than three quarter of the patients. This is major cardiac surgery and may 
compose a larger risk on cardiac failure than isolated valvular surgery. Selection of 
patients for possible VA-ECMO treatment might optimise these results. 
The NYHA class of patients was NYHA class 2 or higher in 69%. A NYHA class of 
2 and higher is a known predictor for mortality (19). Selection of patients for VA-
ECMO using the EURO-SCORE is not validated but may be usable for this group 
of patients (19). Future studies might be able to validate the EURO-SCORE for this 
group of patient. 
Over half of the patients suffered a complication of the treatment, most of these 
being a haemorrhage. This could have led to haemodynamic instability through 
blood loss. It is possible that that may have led to inadequate organ perfusion 
which may impair survival. Strict haemodynamic monitoring and possibly a more 
aggressive approach to possible complications may prevent this and improve 
survival. 
Four of the patients presented in this study were over 70 years old. Patients over 
70 years old generally perform poorly on VA-ECMO and are currently no longer 
eligible for VA-ECMO treatment in our centre. This could have influenced outcome 
and be a possible explanation for the high mortality rate in this study. Moreover 
this is reflected in the significantly lower age of patients who survived. Strict 
adherence to selection of patients of a younger age and forgoing patients over 70 
may improve outcome in this population.  
The neurological outcome is, albeit the low survival rate, good. This illustrated the 
possibility of VA-ECMO to ensure adequate end-organ perfusion. 
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There was only one ECMO related complication. This consisted of clot formation 
in the oxygenator. This is a known complication and may be prevented with strict 
adherence to anticoagulation protocols. However, this is often difficult in septic 
patients in which the septicaemia could influence the anticoagulation.
The mode of cannulation differs between the patients. This could influence survival. 
Femoral cannulation increases afterload for the left ventricle and could influence 
outcome. Central cannulation could overcome this but has the drawback of being 
much more invasive and possibly increasing the risk of infection. The use of left 
ventricular unloading using an intra-aortic balloon pump has been suggested but 
the effect on outcome is uncertain (6,14,20). 
Survival to discharge is low in this study, yet in three patients has led to a favourable 
outcome. VA-ECMO is a costly therapy which needs not only expensive hardware 
but also continuous schooling of staff. If the applicability of this technique is in the 
post-cardiotomy patient who was operated on for infective endocarditis, an ethical 
discussion must be held if it is desirable to spend such a large amount of funds 
and resources on a relatively rare disease with poor outcome. This discussion is 
however beyond the scope of this article but must be held on an international, 
national and individual level with doctors, patients, nurses, allied staff and medical 
ethicists. 
LIMITATIONS
This study has several limitations. It is a small cohort making any statistical analysis 
virtually impossible. It is a retrospective study, with all the associated shortcoming 
of such. The discussion to put patients on VA-ECMO post-cardiotomy may have 
led to a selection bias. As this is an observational study there is no control group 
making comparison impossible. Possibly a future randomised controlled trial may 
solve this issue, however, there are many medical and ethical barriers in doing 
this. 
CONCLUSION: 
VA-ECMO for the treatment of cardiac failure in post-cardiotomy patients who 
were operated on for infective endocarditis is feasible but outcome is poor. It 
could improve survival in selected patients. Further research is needed to identify 
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patients eligible for VA-ECMO treatment for cardiac failure post-cardiotomy in 
infective endocarditis.
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SUBCOSTAL TTE IN VV-ECMO 
CANNULA REPOSITIONING
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A previously healthy 62 year old male with recently diagnosed rapidly progressive 
pulmonary fibrosis was hospitalized and accepted for lung transplantation. During 
admission his pulmonary function critically deteriorated due to an intercurrent 
pneumonia which necessitated additional respiratory support. In order to 
avoid physical deconditioning inherent to invasive mechanical ventilation and 
analgosedation the patient was not intubated. Instead it was decided to follow 
an ‘awake Extra Corporal Membrane Oxygenation (ECMO)’ strategy, which is 
increasingly used as a bridge to lung transplant and allows active participation 
of the patient including physical therapy and training(1).  He was put on Veno-
Venous ECMO (VV-ECMO) using a single site double lumen cannula (Avalon Elite®) 
in the right jugular vein (RJV)(2). During daily care the VV-ECMO flow suddenly 
dropped from 4.3 litres per minute to 2.7 litres per minute. This was followed 
by a significant desaturation in oxygen levels from 99% to around 75%. Patient 
became unresponsive and to avoid possible aspiration of stomach content a 
trans oesophageal echocardiography was deemed too dangerous. Trans thoracic 
echocardiography only produced proper subcostal views due to patient’s supine 
position.
Image A shows a subcostal view. The right atrium (RA in red) right ventricle (RV 
in red) left atrium (LA in red) and left ventricle (LV) are indicated as well as the 
tricuspid valve in blue and the liver and the diaphragm. The cannula position (white 
arrow) is in front of the right atrium passing from superior caval vein to inferior 
caval vein during the initial echo images. The ECMO flow is indicated by the yellow 
arrow. Image B shows the same image with colour Doppler in which the VV-ECMO 
cannula is retracted and turned directing the flow towards the inferior caval vein. 
Image C shows the cannula after slight twisting and pushing it somewhat deeper 
in the RJV with colour Doppler signal aimed more towards the tricuspid valve (red 
arrow). Image D shows the ECMO colour Doppler signal directed towards the 
tricuspid annulus and across after further repositioning (red arrow). The images 
are an example of so-called re-circulation(3). A situation in which part of the ECMO 
flow from the exit cannula containing oxygen rich blood is being directed towards 
the entry cannula and thus re-circulates within the ECMO circuit. This was caused 
by the shift in cannula position due to daily care. In the process the patient is 
being derived from this oxygen rich blood. This together with the decrease in flow 
caused the sudden deterioration in oxygen saturation.
The Successful Use of plain TTE in VV-ECMO cannula repositioning
6B
97 
After repositioning of the VV-ECMO cannula using only subcostal views due 
to patient and technique related circumstances flow of the VV-ECMO circuit 
normalised completely and the patient recovered. He was transferred to a 
designated lung transplantation centre in order to receive a lung transplantation. 
Plain subcostal trans thoracic echocardiography can be successfully used in 
double lumen Avalon cannula repositioning in VV-ECMO when placed in the right 
internal jugular vein.
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Primary percutaneous coronary intervention (pPCI) in ST-elevation myocardial 
infarction (STEMI) can cause great haemodynamic instability. Veno-arterial 
extracorporeal membrane oxygenation (VA-ECMO) can provide haemodynamic 
support in patients with STEMI but data on outcome and complications are scarce. 
Methods: An in-hospital registry was conducted enrolling all patients receiving 
VA-ECMO. Patients were analysed for medical history, mortality, neurological 
outcome, complications and coronary artery disease.
Results
Between 2011 and 2016, 12 patients underwent pPCI for STEMI and received VA-
ECMO for haemodynamic support. The majority of the patients were male (10/12) 
with a median age of 63 (47-75) years and 4 of the 12 patients had a history of 
coronary artery disease. A cardiac arrest was witnessed in 11 patients. The left 
coronary artery was compromised in 8 patients and 4 had right coronary artery 
disease. All patients were in Killip class IV. Survival to discharge was 67% (8/12), 
1-year survival was 42% (5/12), 2 patients have not yet reached the 1-year survival 
point but are still alive and 1 patient died within a year after discharge. All-cause 
mortality was 42% (5/12) of which mortality on ECMO was 33% (4/12). Patient-
related complications occurred in 6 of the 12 patients: 1 patient suffered major 
neurological impairment, 2 patients suffered haemorrhage at the cannula site, 2 
patients had limb ischaemia and 1 patient had a haemorrhage elsewhere. There 
were no VA-ECMO hardware malfunctions. 
Conclusion
VA-ECMO in pPCI for STEMI has a high survival rate and neurological outcome is 
good, even when the patient is admitted with a cardiac arrest.
Keywords: ECMO, STEMI, Cardiogenic Shock, Circulatory Support




Primary percutaneous coronary intervention (pPCI) is the cornerstone in the 
treatment of ST-elevation myocardial infarction (STEMI). STEMI can cause great 
haemodynamic instability through a mechanism of cardiac failure and subsequent 
low output state [1-7]. Haemodynamic support following STEMI is quintessential 
for survival and preservation of cardiac function [6]. Historically, this consisted 
of medical support with inotropes and vasopressors, and mechanical circulatory 
support by an intra-aortic balloon pump [1,3,8,9]. Recently more advanced devices 
have been introduced such as the Impella device, but data on its safety and efficacy 
are inconclusive [10,11]. 
Another form of haemodynamic support is veno-arterial extracorporeal 
membrane oxygenation (VA-ECMO) [12,13]. VA-ECMO can provide haemodynamic 
support in patients with STEMI with cardiac failure and possible concomitant 
respiratory failure due to pulmonary congestion [13-15]. Its mechanism is based 
on the combined possibility of circulatory support through laminar flow of blood 
in the aorta and simultaneous oxygenation of the patient’s blood. Blood flow of up 
to 7 litres/min can be generated in ideal circumstances.
Data on outcome and complications in the use of VA-ECMO in pPCI for STEMI 
are scarce but first reports on this therapy show promising results [6,14-16]. This 
study was performed to gain insight into the outcome and complications of the 
use of VA-ECMO in pPCI for STEMI with subsequent haemodynamic instability. 
METHODS
An in-hospital registry was kept at the St Antonius Hospital, Nieuwegein, the 
Netherlands involving all patients who received treatment with VA-ECMO for 
haemodynamic support from 2009 onwards. Data were collected retrospectively 
and included those patients who received VA-ECMO in addition to pPCI for STEMI. 
All patients were analysed at baseline for age, sex, medical history, previous 
coronary artery disease, coronary artery occlusion in STEMI, concomitant coronary 
artery disease, SYNTAX score, concomitant chronic total occlusion, Survival After 
VA-ECMO (SAVE) score, procedural characteristics including mode of cannulation 
and concomitant use of other circulatory support (e.g. intra-aortic balloon pump 
(IABP)), left ventricular function prior to admission, survival, complications related 
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to the patient (e.g. bleeding at the cannula site, limb ischaemia), complications 
related to the ECMO hardware (e.g. pump failure, clot formation), length of 
ECMO treatment and length of stay on the ICU and in hospital, haemodynamic 
parameters, mortality and neurological outcome [17-19]. 
Shock was defined according to the Killip class [20]. The SYNTAX score was 
calculated using the online SYNTAX score calculator (http://www.syntaxscore.
com/calculator/start.htm) [17]. The SAVE score, an Extracorporeal Life Support 
Organisation (ELSO) endorsed and validated score, was calculated to compare 
predicted mortality with actual morality [18]. This was done by using the online 
SAVE score calculator (http://www.save-score.com/). Neurological outcome was 
defined using the Cerebral Performance Categories Scale (CPC) where a CPC score 
of 1 and 2 was deemed a good neurological outcome [19].
RESULTS
VA-ECMO using the Maquet Cardiohelp, which is a system using an integrated 
rotational pump and oxygenator, was introduced at the St Antonius Hospital 
in Nieuwegein, the Netherlands, a large referral centre, in 2009. From 2009 
until 2016 a total of 118 patients received VA-ECMO for circulatory support for 
various conditions such as post cardiotomy, pulmonary embolism and septic 
shock. Between 2009 and 2016 a total of 19,116 patients underwent coronary 
intervention of which 3673 underwent a PCI for an acute ischaemic event; 12 
patients underwent pPCI for STEMI and received additional VA-ECMO treatment 
for haemodynamic support. The first VA-ECMO in addition to STEMI was performed 
in 2011.
Baseline characteristics
The majority of patients were male (83%,10/12) with a median age of 63 (47-75) 
years with only 1 patient over the age of 70 years. A history of coronary artery 
disease in the form of a previous PCI was present in 33% (4/12) of the patients of 
whom 1 patient had recently diagnosed left main disease. None of the patients 
had undergone previous cardiac surgery and none had known left ventricular 
impairment prior to admission. None of the patients had a history of neurological 
events in the form of either a transient ischaemic attack or a cerebrovascular 
accident. Only 1 patient had known pulmonary disease in the form of chronic 
obstructive pulmonary disease GOLD class 1/4. Two patients had a history 
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of diabetes mellitus type 2 and 42% (5/10) were known to have a history of 
hypertension. There was 1 patient with a history of peripheral artery disease in the 
form of implantation of an aortic bifurcation prosthesis 11 years prior to primary 
pPCI for STEMI. All patients were in cardiogenic shock, Killip class 4 prior to and 
after pPCI (Table 1).
Baseline Characteristics N=12
Male 83%   (10/12)
Age 63      (47-75) years
Previous Coronary Artery Disease 33%   (4/12)
Diabetes 17%   (2/12)
Hypertension 42%   (5/12)
TIA/Stroke NA
COPD  8%    (1/12)
Per peripheral artery disease 8%     (1/12)
Shock upon admission, Killip class IV 100% (12/12)
Table 1 Baseline Characteristics. Abbreviations: TIA: Transient  Ischaemic Attack, COPD: 
Chronic Obstructive Pulmonary Disease, NA: Not Available
Procedural characteristics
The indication for VA-ECMO was determined by the attending interventional 
cardiologist and intensivist. An out-of-hospital cardiac arrest (OHCA) prior to 
presentation was witnessed in 9 of the 12 patients. Two patients suffered an in-
hospital cardiac arrest. The left coronary artery was involved in 67% (8/12) of the 
patients: 3 left main coronary arteries, 5 left anterior descending arteries and 
the other 4 patients had right coronary artery disease. The mean SYNTAX score 
was 23.7 (4-40). A total of 8 patients had concomitant coronary artery disease, 
3 of which had a chronic total occlusion of another coronary artery than the 
culprit lesion. Culprit lesion revascularisation was achieved in 92% (11/12). One 
patient had an unsuccessful evacuation of thrombus in the right coronary artery. 
One patient had successful revascularisation of the culprit lesion but received a 
coronary artery bypass graft (CABG) after pPCI. 
Mean systolic blood pressure was 70 (53-80) mmHg upon admission while mean 
pH was 7.2 (6.97-7.40) and mean lactate was 6.4 (1.6-12.0) mmol/l. Mean blood 




All patients were cannulated at the Cathlab. The cannula was inserted in the 
femoral artery in 9 of the 12 patients. In 3 patients the cannula was placed in the 
subclavian artery by the attending cardiothoracic surgeon. The venous cannula 
was placed in the femoral vein in all but 1 patient, where it was placed in the 
internal jugular vein. Two patients had an IABP in situ at the time of cannulation. 
The mean SAVE score was -5.5 (-2 - -11) which represents an estimated survival of 
30% (25%-35%) (Table 2).
Initially the patients were weaned off the device according to the clinical judgement 
of the attending physician. However, after 2015 the patients were weaned off the 
device using the local weaning protocol, which is a modification of an existing 
protocol [21].
Procedural characteristics N=12
Out of hospital cardiac arrest 75% (9/12)
In hospital cardiac arrest 17% (2/12)
Left coronary artery 67% (8/12)
Right coronary artery 33% (4/12)
Culprit revascularisation 92% (11/12) 
SYNTAX Score 23.7 (4-40)
Intra-Aortic Balloon Pump 17% (2/12)
Subsequent CABG after PCI 8%   (1/12)
SAVE Score -5.5   (-2 - -11)
Table 2 Procedural Characteristics. Abbreviations: CABG: Coronary Artery Bypass Grafting. 
PCI: Percutaneous Intervention  
Outcome
Survival to discharge was 67% (8/12), 1-year survival was 42% (5/12), and 2 of the 12 
patients have not yet reached the 1-year survival point but are still alive. Mortality 
on VA-ECMO was 33% (4/12) and this was also the 30-day mortality. All patients 
who survived VA-ECMO survived to discharge. All-cause mortality was 42% (5/12); 
The aforementioned 33% (4/12) of patients who died on VA-ECMO and 1 patient 
who died within a year after discharge due to aspiration pneumonia caused by 
poor neurological status after prolonged cardio-pulmonary resuscitation. 
Both the patients who received IABP and ECMO survived to discharge. The patient 
who suffered unsuccessful evacuation of the thrombus in the right coronary 
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artery did not survive. The patient who underwent subsequent CABG did survive 
to discharge. 
Patient-related complications occurred in 6 of the 12 patients: 2 patients suffered 
haemorrhage at the cannula site and 1 patient had a haemorrhage elsewhere in 
the form of a venous haemorrhage of the liver due to the venous cannula position 
while on VA-ECMO. Limb ischaemia occurred in 3 of the 12 patients; in 1 of these 
patients the right leg was eventually amputated due to clot formation between 
the ECMO cannula and antegrade leg perfusion. One patient suffered major 
neurological impairment; however, this was not due to intracranial haemorrhage 
but due to prolonged resuscitation prior to receiving the VA-ECMO treatment. 
There were no malfunctions regarding the VA-ECMO hardware. The median time 
spent on VA-ECMO was 5 (1-10) days, the median time spent on the ICU was 14 (1-
68) days and the median time spent in hospital was 23 (1-82) days (Table 3).
Outcome N=12
Survival to discharge 67% (8/12)
Survival with >1 year follow up 42% (5/12)
All-cause mortality 42% (5/12)
Mortality on ECMO 33% (4/12)
30 days mortality 33% (4/12)
Mortality after discharge  8%  (1/12)
All Complications 50% (6/12)
Major Neurological impairment  8%  (1/12)
Haemorrhage cannula 17% (2/12) 
Haemorrhage elsewhere  8%  (1/12)
Limb ischaemia 25% (3/12)
Median time on ECMO 5   (1-10) days
Median time on ICU 14 (1-82) days
Table 3 Outcome: Abbreviations: ECMO: Extra Corporal Membrane Oxygenation. ICU: 
Intensive Care Unit 
Follow-up after VA-ECMO in pPCI for STEMI
Of the 12 patients who received VA-ECMO in pPCI for STEMI, 1 patient received 
a CABG for concomitant coronary artery disease. Another patient underwent 
implantation of a left ventricular assist device (LVAD) in a designated LVAD centre. 




This study shows that VA-ECMO is feasible in selected patients. It could potentially 
improve survival in patients undergoing primary PCI for STEMI with cardiogenic 
shock. As all patients were in cardiogenic shock, VA-ECMO could be considered a 
last resort therapy. There are no randomised trials on VA-ECMO in pPCI in STEMI; 
observational studies proving the concept of circulatory support with VA-ECMO 
in pPCI in STEMI are crucial in facilitating future research in this field [13-16]. In 
this observational study VA-ECMO was feasible, safe and with a relatively low 
complication rate in a very high-risk group of patients with great haemodynamic 
instability. As our research shows, the applicability of this possibly life-saving 
technique in patients undergoing pPCI for STEMI can be the start of a future 
randomised controlled trial proving its use in pPCI in STEMI. 
Although the SAVE score is not a substitute for clinical assessment of patients, the 
difference between the predicted mortality and the actual mortality may illustrate 
that VA-ECMO is especially useful in the treatment of cardiogenic shock caused by 
STEMI. 
Only 1 patient suffered a poor neurological outcome due to prolonged 
resuscitation prior to pPCI and VA-ECMO cannulation. This illustrates the safety of 
using VA-ECMO in haemodynamic support with respect to possible neurological 
injury. Three patients suffered limb ischaemia. This is a known complication of VA-
ECMO due to occlusion of the femoral artery distal of the cannula and the cannula 
itself. The correct use of antegrade leg perfusion via insertion of an extra small 
diameter cannula can prevent this (known as leg-ECMO or L-ECMO). However, 1 
patient had adequate leg perfusion but developed clot formation between the 
retrograde ECMO cannula and antegrade leg perfusion. Surgical exploration 
during decannulation could prevent this. Studies in this regard are lacking and 
a standardised procedure of decannulation might prevent this complication. No 
intracranial haemorrhages were reported, although patients on VA-ECMO received 
dual antiplatelet therapy and heparin infusion for the ECMO circuit. This indicates 
the safety of the described procedure from a neurological point of view. 
One of the possible drawbacks of VA-ECMO in pPCI for STEMI is the increase 
in afterload of the heart. This is a direct result of competitive flow of the ECMO 
circuit with the cardiac circulation [22]. However, as one of the major problems 
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of cardiogenic shock is poor organ perfusion with subsequent organ failure, 
adequate organ perfusion is pivotal in improving patient survival and may 
outweigh the problem of increased afterload. In our study increased afterload did 
not lead to a worsening of the outcome for patients. If increasing afterload poses 
a problem in the treatment of patients on VA-ECMO, the use of an IABP or Impella 
device for left ventricular unloading may be considered. However, the possible 
benefit of left ventricular unloading is purely theoretical and not yet proven in a 
clinical setting. Furthermore, the use of an IABP or Impella or other left ventricular 
unloading device may increase the risk of possible complications, the complexity 
of the procedure as well as the cost of treatment. In this study, 2 patients received 
concomitant IABP therapy during VA-ECMO treatment and survived to discharge. 
This illustrates the technical feasibility of these two combined techniques.
Two of the described patients underwent VA-ECMO treatment in pPCI for STEMI 
and received additional therapy after pPCI in the form of a CABG and LVAD 
placement. This underlines the possibility of using VA-ECMO as a bridge to LVAD, 
treatment or recovery. 
In this study, all patients were placed on VA-ECMO after PCI. In future studies 
patients could be placed on VA-ECMO prior to PCI. The first strategy has the 
benefit of earlier revascularisation, but it prolongs poor organ perfusion and 
haemodynamic shock. The second strategy may delay revascularisation by 
several minutes but allows early haemodynamic support and stabilisation as VA-
ECMO therapy can be administered directly in the Cathlab. Future research must 
establish the ideal timing of VA-ECMO placement.
The absence of ECMO-related hardware failure is a possible indication of the 
reliability of the Maquet Cardiohelp. It can be safely used in this group of patients. 
LIMITATIONS
Our study has several limitations. It is an observational study comprising only a 
small number of patients. As patients were selected for VA-ECMO by the attending 
physicians, selection bias is present. Furthermore, there was no control group; 
future studies may be able to randomise patients undergoing pPCI for STEMI with 
subsequent cardiogenic shock to VA-ECMO treatment versus medical treatment. 
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The small number of patients in this study makes any sound statistical conclusion 
impossible, In future registries with larger numbers of patients this can be 
overcome. 
CONCLUSION
In our group, VA-ECMO in pPCI for STEMI had a survival to discharge rate of 67% 
and even when patients were admitted with an OHCA this outcome was favourable. 
The complication rate was relatively low and neurological outcome was good. 
Further research is needed to identify the patients most likely to benefit from VA-
ECMO treatment in pPCI for STEMI. Randomised controlled trials are needed to 
prove the efficacy of this new and promising technique.
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Complex high risk percutaneous coronary intervention (PCI) is challenging and 
frequently accompanied by haemodynamic instability. Veno-arteial extra corporal 
membrane oxygenation (VA-ECMO) can provide cardiopulmonary support in high 
risk PCI however outcome is unclear. 
Methods
A two-centre registry of all patients undergoing high risk PCI and receiving VA-
ECMO for cardiopulmonary support.
Results
A total of 14 patients (92% male, median age 69 (53-83)) years of which 50% had 
previous coronary artery disease in the form of a CABG (36%) and a PCI (14%) 
underwent high risk PCI and received  VA-ECMO support. The main target lesion 
was a left main in 78%, a LAD in 14%, a RCA in 7% and 71% underwent multi vessel 
PCI in addition to main target vessel PCI. The median Syntax score was 27.2 (8-
42.5) and in 64% (9/14) there was a CTO lesion. LV function was mildly impaired 
in 7% (1/14), moderately  impaired in 14% (2/14) and severely impaired in 64% 
(9/14). Cannulation was femoral-femoral in all patients. Median ECMO run was 
2.57 hours (1-4)
Survival was 93% (13/14). One patient died during hospitalisation due to refractory 
cardiac failure. All other patients survived to discharge. Complications occurred in 
14% (2/14) with one patient developing a transient ischaemic attack post ECMO 
and one patient developing a thrombus in the femoral vein used for ECMO 
cannulation.
Conclusion
VA-ECMO in high risk PCI is feasible with good outcome. It can be successfully used 
for cardiopulmonary support in selected patients. 
Keywords:  Veno-arterial extracorporeal membrane oxygenation · Percutaneous 
coronary intervention · High-risk percutaneous coronary intervention · Chronic 
total occlusion




Patients with stable complex coronary artery disease, e.g. three vessel disease, 
left main disease or one or more chronic total occlusions (CTO) who need 
revascularisation can be treated with either percutaneous coronary intervention 
(PCI) or coronary artery bypass graft (CABG) [1]. Usually these patients are 
discussed in a Heart Team where several risk stratification scores can be used to 
determine the risk of either form of revascularisation and make a well-considered 
decision about the most appropriate  revascularization strategy [1]. Examples of 
these score are the Syntax, Syntax II, EURO-score and for CTO’s the J-CTO score 
[1-4]. For many years, CABG was the treatment of choice for multi-vessel coronary 
artery disease, especially in diabetic patients [2,5]. In the last decade or so studies 
have shown that for noncomplex multi-vessel coronary artery disease,  CABG 
and PCI have equal outcomes [3]. For complex multi-vessel disease however, 
guidelines still advise CABG over PCI [1].
Nonetheless, a considerate group of patients is not suitable for surgical 
revascularization. This group comprises patients with advanced age, multiple 
comorbidities, poor left ventricular function, earlier cardiothoracic surgery, or 
a combination of these factors. Until recently, treatment for these patients was 
either conservative of very high risk PCI with a high chance of peri-procedural 
mortality. 
Complex high risk PCI can cause hemodynamic instability through a mechanism of 
procedure induced ischemia of the heart. This can cause acute heart failure and 
lead to detrimental outcome of elective percutaneous interventions.
Historically high risk PCI could be performed under mechanical circulatory 
support using the Intra Aortic Balloon Pump (IABP) but its use has seen a decline 
and downgrade in this regard as studies have failed to display a clear benefit 
of this form mechanical circulatory support [6-8]. Recently, high risk PCI under 
mechanical support, especially extracorporeal membrane oxygenation (ECMO) 
and Impella, has been established as a possible alternative for this group of high 
risk patients [9-12].  Initial reports on the use of VA-ECMO showed promising 
result in the treatment of cardiogenic shock due to myocardial infarction [13-15]. 
Patients with stable coronary artery disease have also been re-vascularised with 
mechanical support using VA-ECMO however data on outcome and procedural 
characteristics is scarce [9,10].
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The current study aims at describing patient characteristics, procedural findings 
and outcome in the of VA-ECMO for mechanical circulatory support in elective 
high risk PCI.
METHODS
A two-centre retrospective study, including all patients that underwent elective 
very high risk PCI under ECMO for stable coronary artery disease in the past 18 
months was performed. All patients were analysed for age, gender, previous 
medical history including diabetes, hypertension, peripheral artery disease, 
tobacco use, renal function where a eGFR<60 (stage 3) was considered an impaired 
renal function and the presence of a malignant proliferative disease [16]. 
Patients were selected by the attending interventional cardiologist who would also 
perform the ECMO assisted PCI. In none of the two participating centres another 
form of mechanical circulatory support capable of providing full mechanical 
circulatory support was available at the time other than VA-ECMO. 
Cardiac status was analysed in regard to previous coronary artery disease, previous 
cardiac surgery which was divided into previous CABG and valvular surgery. Left 
ventricular function was assed using the available imaging modalities for each 
patients including trans thoracic echo and nuclear imaging when available. 
Left ventricular function was defined as good (>55%), mildly impaired (45-55%), 
moderately impaired (35-45%) or severely impaired (<35%)  [17]. 
Procedural characteristics were analysed on number of target vessels that were 
re-vascularized in which all separate braches were counted as one separate vessel, 
achievement of complete revascularization, duration of ECMO run in hours, limb 
ischemia, post-procedural admission to the intensive care unit, thromboembolic 
complications, acute renal failure defined as a increase of >1 stage of renal 
failure above baseline, the need for haemodialysis, drop in haemoglobin post 
procedure, drop in thrombocytes count post procedure, neurological outcome 
where a cerebral performance category (CPC) scale of 1 and 2 was deemed a 
good neurological outcome, major adverse cardiovascular events (MACE) during 
admission, re-infarction and mortality at discharge [18]. 
For all patient the Syntax score I and II were calculated in order to asses coronary 
anatomy using the on-line calculator (http://www.syntaxscore.com/calculator/
Prophylactic Veno-Arterial Extra Corporal Membrane Oxygenation
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start.htm)  and for all patients the J-CTO score was also calculated when 
appropriate to asses lesion anatomy and complexity using the on-line J-CTO 
score sheet (https://www.incathlab.com/files/COURSES/CTO/jcto-score-sheet.
pdf). Furthermore, for all patients the EURO-score I and II were calculated to asses 




Between January 2017 and august 2018, a total of 14 patients underwent high risk 
PCI under prophylactic VA ECMO support in two hospitals in the Netherlands. The 
majority was male (92%) with a median age of 69 (53-83) years and with 50% of all 
patients being over 70 years old. A previous history of hypertension was present 
in 57%, diabetes mellitus in 21%, documented hypercholesterolemia in 29% and 
43% was known to have peripheral artery disease. Non patients had an active 
malignancy at the time of this study. Renal function was impaired (eGFR<60, stage 
≥3) in 21%. Median haemoglobin levels prior to mechanical circulatory support 
was 8.2 (6.9-9.8) mmol/L and median thrombocyte count was 271 (166-594) 
mmol/L. (see table: 1)
Baseline characteristics (demographics, risk factors and biochemical values)
Age (years) 69 (53-83)
Male sex 92% (13/14)
Diabetes mellitus 21% (3/14)
Hypercholesterolemia 29% (4/14)
Hypertension 57% (8/14)
Peripheral arterial disease 43% (6/14)
Malignancy 0% (0/14)
Smoker 29% (4/14)
Impaired renal function (eGFR <60, stage ≥3) 21% (3/14)
Hemoglobin (mmol/L) 8.2 (6.9-9.8)
Thrombocytes (mmol/L) 271 (166-594)
Table 1 Baseline characteristics (demographics, risk factors and biochemical values)
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Assessment of cardiac anatomy and function
Half of the patients had undergone pervious coronary revascularisation in the 
form of CABG (36%) or PCI (14%). Left ventricular function was severely impaired 
(ejection fraction <30%) in most patients, 71% in total. In 21% the left ventricular 
ejection fraction was moderately impaired and in 7% mildly impaired. Main target 
vessel was left main in 71% of cases, LAD in 21% of cases, and RCA in 7%. Additional 
PCI of the non target vessel was performed in 71%. Target vessel was a CTO in 79% 
of the lesions. Median syntax I score was 34, median J-CTO score was 1 (0-3) (mean 
1.55 SD 0.93). The median Syntax score was 34 (8-42.5), the median Syntax score 
II (PCI) was 53.5 (26.2-79.5) and the median Syntax score II (CABG) was 40.1 (16.2-
57.2). (see table 2)
Baseline characteristics (cardiac history, anatomy and risk scores)
Prior coronary artery disease 57% (8/14)
Prior CABG 36% (5/14)
Previous valvular surgery 0% (0/14)






LVEF >55% 0% (0/14)
LVEF 45%-55% 7% (1/14)
LVEF 35%-45% 21% (3/14)
LVEF <35% 71% (10/14)
EURO-score I 7.1 (3.6-34.1)
EURO-score II 3.2 (0.9-16.8)
Syntax score I 34 (8-42.5)
Syntax score II (PCI) 53.5 (26.2-79.5)
Syntax score II (CABG) 40.1 (16.2-57.2)
J-CTO score (median for all CTO lesions) 1 (0-3)
Table 2 Baseline characteristics (cardiac history, anatomy and risk scores) abbreviations: 
CABG: Coronary Artery Bypass Graft,  LM: Left Main, LAD: Left Anterior Descending, RCA: 
Right Coronary Artery, RCx: Ramus Circumflex, CTO: Chronic Total Occlusion, LVEF: Left 
Ventricular Ejection Fraction.
Procedural characteristics
Prior to cannulation al patients were intubated and put on mechanical ventilation. 
Cannulation was femoral-femoral in all patients. None of the patients received 
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ante-grade perfusion of the leg during the procedure. All patients were cannulated 
by the attending cardiothoracic surgeon. Median ECMO run was 2.57 hours (1-
4). All patients were decannulated at the catheterisation laboratory  without 
complications by the cardiothoracic surgeon in an open procedure. None of the 
patients was admitted to the ICU after the procedure. All patients were transferred 
to the  coronary care unit uneventfully. 
Outcome 
PCI was successful in 100% of patients with revascularization of all target and 
additional lesions. Survival to hospital discharge was 93%. One patient died 
during hospitalization due to refractory cardiac failure due to end stage heart 
failure which was not attributed to either the PCI or the VA-ECMO support by 
the attending physician. All other patients were discharged neurologically intact 
with a CPC of 1. ECMO related complications occurred in 14% of patients, with 
one patient developing a transient ischemic attack after the procedure and one 
patient developing a thrombus in the femoral vein used for cannulation several 
days after decannulation. One patient was re admitted after several months with 
a re-infarction. The median drop in haemoglobin was 2.0 (0.4-3.0) mmol/L and the 
median thrombocyte count drop was 82 (16-107) mmol/L. (see table 3)
Procedural characteristics and outcomes
Complete revascularisation 100% (14/14)
Duration of ECMO (hours) 3 (1-4)
Limb ischemia 0% (0/14)
Postprocedural admission to ICU 0% (0/14)
Thromboembolic complication 14% (2/14)
Renal insufficiency post-procedural (increase 
≥1 stage above baseline)
21% (3/14)
Need for haemodialysis 0% (0/14)
Hemoglobin drop (mmol/L) 2.0 (0.4-3.0)
Thrombocytes drop (mmol/L) 82 (16-107)
MACE during admission 14% (2/14)
Re-infarction 7% (1/14)
Mortality at discharge 7% (1/14)
Table 3 Procedural characteristics and outcomes. Abbreviations: ECMO: Extra Corporeal 




The present study reports patient and procedural characteristics and short term 
outcome of 14 patients who underwent high risk PCI for stable coronary artery 
disease under prophylactic VA ECMO support. Mortality and complications were 
low and despite the highly complex and mostly extensive coronary artery disease 
of these patients, PCI was successful in all cases. 
PCI under ECMO in unstable patients with STEMI and/or cardiogenic shock has been 
reported as relatively safe with good outcome [9,13]. Literature about high risk PCI 
under ECMO support in stable patients, however, is scarce up to date. Tomasello 
et al. have shown excellent 6 month outcome in a prospective study with 12 
patients with stable coronary artery disease, however complete revascularization 
was accomplished in only 50% of these patients [19]. The present retrospective 
study shows similar short term outcome however with complete revascularization 
in all patients. This might be explained by operator experience. A large portion of 
the patients had know CTO lesions and it is in this specific group of patients that 
results are operator dependent. Highly skilled and experienced operators as well 
as clear revascularization strategies heighten the change of success.   
Decision-making about whether or not a specific patient requires hemodynamic 
support during high risk PCI is not easy. Several factors are to be considered, 
such as left ventricular function, comorbidities, previous revascularizations, 
expected duration and complexity of PCI and expected ischemic burden during 
PCI. For example, PCI of unprotected left main, especially when accompanied with 
significant RCA disease - or even CTO, can lead to massive ischemia. Expected 
duration of balloon inflation and risk of complications such as dissection have 
to be estimated beforehand. Ostial LM lesions might lead to shorter duration of 
ischemia than complex Medina 1,1,1 distal LM lesions, for example. Coronary 
anatomy must be taken into account when selecting patients for ECMO assisted 
revascularization. 
In the present study, patient characteristics and extent of coronary artery disease 
vary widely. This is reflected by the EURO I and II  score and Syntax I and II score. 
This emphasizes the fact that high risk factors are partially incorporated in these 
risk stratification scores, but individual assessment and tailored decision making 
stays of the utmost importance. 
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Local expertise with VA-ECMO and availability of trained personnel is also a key 
factor applying this new technique. In the participating hospitals, the majority of 
patients have been referred from another hospital. This includes hospitals with 
cardiac interventional facilities but without expertise and availability of ECMO. In 
the future, increase of experience with this new strategy in hemodynamic support 
may increase favourable outcome and further reduce complications.
In prolonged ECMO therapy one of the major complications that can arise is leg 
ischemia due to occlusion of the femoral artery due to the arterial cannula. None 
of the patients in this study received ante-grade perfusion of the leg (so called Leg-
ECMO or L-ECMO) yet none of the patients developed leg ischemia. This underlines 
the safety of the procedure in respect to distal limb perfusion. 
Use of femoral- femoral VA-ECMO increases afterload for the left ventricle which 
is already being stressed by the PCI itself. This may cause a less optimal outcome. 
Simultaneous use of either the intra-aortic balloon pump (IABP) or Impella device 
has shown to improve outcome in cardiogenic shock and may be considered to 
reduce afterload [20]. However this does make the procedure more complex, the 
aorta crowded with several devices which may hamper catheter placement as well 
as femoral access being unavailable for catheter access. It will also greatly increase 
the costs. In this study, ECMO use alone has shown good outcome and no form of 
afterload reduction was used. Possibly the short duration of the use of ECMO as 
mechanical circulatory support may not necessitate afterload reduction. 
All patients were cannulated and decannulated by the attending surgeon. This 
may increase safety of the procedure but it will also stretch resources that could 
be otherwise put to good use. As experience with large bore cannula’s is increasing 
(e.g. TAVI) and closure devices are more and more being used successfully (e.g. 
Manta closure device®, Perclose closure device®) future procedures could be 
done fully percutaneous with surgical expertise on-site. This may increase patient 
comfort, reduce scarring and also reduce cost of the procedure. 
In the application of VA-ECMO in the treatment of cardiogenic shock regardless 
of its cause age plays a major role in outcome. Patients of over 70 are generally 
excluded from this form of mechanical circulatory support as they do quite poorly 
in respect to outcome and complications [13]. In the study however half of the 
patients is over 70 years old with some being even over 80 years old and they 
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do very well. This might be an indication that this revascularization strategy with 
mechanical circulatory support is applicable to a much higher age group than 
ECMO support for cardiogenic shock is. 
Next to prophylactic ECMO support, as was used in all patients in our present 
study, one might also consider provisional ECMO support. In this strategy, ECMO 
equipment and trained personnel will be readily available when needed, but only 
used when hemodynamic problems occur during the PCI procedure. An ECMO 
circuit will be present in the catheterisation laboratory, ready for use when 
needed. This might lead to less ECMO related complications, reduce cost but on 
the downside, this strategy might lead to a delay in the treatment of cardiogenic 
shock and may increase poor outcome when cardiogenic shock occurs. Literature 
on provisional ECMO support is virtually absent when compared to prophylactic 
ECMO support. In the future, randomized trials will be necessary to answer this 
question and determine the best strategy in revascularization with mechanical 
circulatory support.
Besides ECMO, other hemodynamic support systems are also available. This 
comprises Impella, IABP, Tandemheart and PulsCath. Of these devices, IABP 
gives a relatively low increase in cardiac output nut has shown an improvement 
in outcome in the BCIS-1 trial [21]. In a prospective study by Kovacic et al, direct 
comparison in stable patients with 3 vessel disease and impaired left ventricular 
function shows that Impella is associated with a significant lower incidence of 
major adverse events in 90 days than IABP [11]. The advance of Impella is that it 
is less invasive. The disadvantage is that it only provides flow but does not ensure 
end organ perfusion. Furthermore the presence of the Impella device might 
hamper catheter placement in the aorta. ECMO is more invasive but will ensure 
end organ perfusion and will not disturb catheter placement in the aorta. Direct 
comparison of prophylactic Impella and VA-ECMO support in high risk PCI patients 
has not yet been performed to our knowledge. Local availability and expertise will 
largely guide the choice for which hemodynamic support device to use until there 
is a head to head comparison of these two techniques. Two other devices have 
been used for mechanical support during high risk PCI. The Tandemheart shows 
similar results to the Impella [22]. The PulsCath has demonstrated feasibility and 
safety in this group of patients and first reports on outcome show promising 
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results [23,24]. A future head to head comparison between the different support 
modalities must show which of these is most suited in this group op patients.
CONCLUSION: 
Our study shows good feasibility and good short term outcome of prophylactic VA-
ECMO supported PCI in stable high risk patients. Mortality and complication rate 
is low. It can be safely used to provide mechanical circulatory support in patients 
undergoing high risk PCI.
However, more prospective research and head to head comparison with other 
support devices is indicated to determine the best strategy in this vulnerable and 
high risk group of patients 
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CHAPTER 9
IABP AND VA-ECMO IS ASSOCIATED 
WITH BETTER OUTCOME THAN VA-
ECMO ALONE IN THE TREATMENT 
OF CARDIOGENIC SHOCK IN 
ST-ELEVATION MYOCARDIAL 
INFARCTION
FS van den Brink, C Zivelonghi, T Vossenberg, G Bleeker, VL Winia, KD Sjauw, JM 
ten Berg 




To asses if combining VA-ECMO with IABP improve outcome in STEMI over ECMO 
alone
BACKGROUND 
VA-ECMO is an upcoming technique in the treatment of cardiogenic shock however 
it increases afterload. IABP in addition to VA-ECMO has been suggested to reduce 
afterload and increase survival.
METHODS
A multi-center in-hospital registry was kept on all patients undergoing VA-ECMO or 
VA-ECMO and IABP treatment for cardiogenic shock in STEMI.
RESULTS
Between 2015 and 2018, 18 patients with STEMI underwent VA-ECMO +/- IABP 
treatment for cardiogenic shock. The majority was male (78% (14/18)), median age 
of 59 (47-75) years. VA-ECMO+IABP was performed in 39% (7/18) and 61% (11/18) 
received VA-ECMO alone.  
The ECMO+IABP group had more complex coronary anatomy with a higher 
number of patients with  left main (LM) disease, LM + 3-vessel disease or 3 -vessel 
disease (ECMO+IABP 86% vs ECMO alone 18% p=0.03). The SAVE score did not 
differ between the groups (ECMO alone -5.9±2.4 vs ECMO+IABP -6.1±2.6 p=0.88).
The Syntax score was higher in the ECMO+IABP (ECMO alone 22 ±14 vs ECMO+IABP 
32 ±13).  In the total group, a SAVE score of -6 had a predicted survival of 25-35%. 
Survival in the VA-ECMO+IABP group was 100% (7/7), survival in the VA-ECMO 
group was 55% (6/11) p=0.035. Good neurological outcome was achieved in more 
patients in the ECMO+IABP group (ECMO alone 45% vs ECMO+IABP 100% p=0.037). 
CONCLUSION
In STEMI complicated by cardiogenic shock VA-ECMO combined with IABP leads 
to a lower observed mortality and higher observed good neurological outcome. 
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Abbrevations: VA-ECMO: Veno-arterial extra corporeal membrane oxygenation. 
IABP: intra-aortic balloon pump. STEMI ST: elevation myocardial infarction. pPCI: 
primary percutaneous intervention. BMI: body mass index. LVEF: left ventricular 
ejection fraction. CPC: cerebral performance categories. GFR: glomerular filtration 
rate
Keywords: Extra Corporeal Membrane Oxygenation, Intra-Aortic Balloon Pump, 
ST-elevation Myocardial Infarction
INTRODUCTION
ST elevation myocardial infarction (STEMI) can cause great hemodynamic 
instability due to acute heart failure and this is associated with poor outcome [1-3]. 
Traditionally intra-aortic balloon pump (IABP) was used for mechanical circulatory 
support but it has seen a decline in indication [4-8]. Veno-arterial extra corporeal 
membrane oxygenation (VA-EMCO) is an upcoming technique in the treatment of 
cardiogenic shock and the first results with this technique have shown promising 
results [9-12]. It has recently been introduced in the European Society of 
Cardiology guideline as a IIB indication for the treatment of cardiogenic shock [7, 
13]. One of the drawbacks of VA-ECMO, however, is the increase of afterload for 
the left ventricle, especially in femoral-femoral  percutaneous cannulation which 
is almost always the case in the setting of  STEMI [9]. This increased afterload 
causes a higher oxygen consumption by the myocardium as well as increased left 
ventricular (LV)-pressures leading to injury upon insult of the already infarcted 
myocardium [14, 15]. Currently there is much debate if left ventricular unloading 
is necessary. The use of Impella (Abiomed) (the so-called Ecmella), left ventricular 
venting and concomitant ECMO and IABP use have all been suggested to achieve 
this, but evidence on the best strategy is lacking [14, 15]. There are no physiological 
studies in this area and currently only computer simulations are available to give 
insight in the role of left ventricular unloading during ECMO for cardiogenic shock 
[14]. Combination of VA-ECMO and IABP has been suggested to reduce afterload 
and increase survival but there is very little real world evidence [9].
METHODS 
A multi-center in hospital registry was kept on all patients undergoing VA-ECMO 
or VA-ECMO and IABP treatment for cardiogenic shock in addition to primary 
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percutaneous intervention (pPCI) in STEMI in four different hospitals in Europe . All 
patients were analysed at baseline for age, sex, medical history, previous coronary 
artery disease, renal function, diabetes, body mass index (BMI), culprit lesion and 
target vessels, concomitant coronary artery disease,  procedural characteristics 
including mode of cannulation, left ventricular ejection fraction (LVEF) before 
admission and after admission, patient related complications (e.g. bleeding at the 
cannula site, limb ischaemia), ECMO hardware related complications (e.g. pump 
failure, clot formation), length of ECMO treatment and length of stay on the ICU 
and in hospital, haemodynamic parameters including cardiac arrest, mortality 
and neurological outcome. Haematological parameter were also observed and 
included haemoglobin, haematocrit, platelet count and lactate levels.
Cardiogenic shock was defined using the Killip class system [3]. 
In order to assess coronary anatomy the SYNTAX score was calculated using 
the online SYNTAX score calculator (http://www.syntaxscore.com/calculator/
start.htm) [16, 17]. The SAVE score, an Extracorporeal Life Support Organisation 
endorsed and validated score, was calculated to compare the predicted mortality 
with the actual morality [18]. This was done by using the online SAVE score 
calculator (http://www.save-score.com/). Neurological outcome was defined using 
the Cerebral Performance Categories Scale (CPC) where a CPC score of 1 and 2 
was considered  good neurological outcome [19]. Renal function was assed using 
the glomerular filtration rate (eGFR) [20]. 
Statistical analysis was performed using chi-square and T-test to compare 
categorical and continuous variables.
Although according to Dutch law (Wet Medisch Wetenschappelijk Onderzoek 
met Mensen) no approval of a medical ethical committee is needed this was 
performed anyway which saw no ethical conflict regarding this study. All patients 
were treated using the Maquet Cardiohelp ®, an integrated pump system which 
can generate flows of up to 7 liter per minute and the Maquet CS300™ IABP which 
has a pulsatile volume of 50cc (Maquett/Gettinge group, Rastatt Germany).
RESULTS 
Between 2015 and 2018, 18 patients with STEMI underwent VA-ECMO +/- IABP 
treatment for cardiogenic shock. The majority was male (78% (14/18)) with a 
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median age of 59 (47-75) years.  VA-ECMO and IABP was performed in 39% (7/18) 
and 61% (11/18) received VA-ECMO alone. All patients were in Killip class IV prior 
to admission, were  on vasopressors and inotropes and all patients received VA-
ECMO support in the cathlab in addition to pPCI for STEMI. The patients in the 
IABP+ECMO group received IABP support in the catheterization laboratory prior to 
PCI. Both the patients in the ECMO alone group and the ECMO+IABP group received 
ECMO cannulation in the catheterization laboratory after PCI was performed. 
Indication for either procedure was made by the attending cardiologist. All patients 
underwent femoral-femoral cannulation.
Baseline
When comparing the ECMO alone group vs the ECMO+IABP group there was no 
significant difference in age (59±7 vs 59±7 p=0.89), diabetes (9% vs 43% p=0.09), 
known coronary artery disease (36% vs 0% p=0.07), hypertension (45% vs 14% 
p=0.31), know reduced LVEF (0% vs 0% p=1.0) or eGFR (56±27 vs 59±7 p=0.88). 
There was however a difference in BMI with patients in the ECMO alone group 
being significantly heavier (29.1±3.8 vs 24.5±1.98 p=0.02). In both groups a large 
number of patients suffered a cardiac arrest prior to or during admission (ECMO 
alone 91% vs ECMO+IABP 71% p=0.52). The SAVE score did not differ between the 
groups (ECMO alone -5.9±2.4 vs ECMO+IABP -6.1±2.6 p=0.88). A SAVE score of -6 
has a predicted survival of 25-35%. (see table 1. Baseline)
 ECMO alone (n=11) ECMO + IABP (n=7) p Value
Age 59±7 59±11 0.98
Male Gender 9 (82%) 6 (86%) 0.99
BMI 29.1±3.8 24.5±1.98 0.02
Diabetes 1 (9%) 3 (43%) 0.09
CAD 4 (36%) 0 0.07
Hypertension 5 (45%) 1 (14%) 0.31
LVEF <55% 0 0 1.0
eGFR 56±27 59±7 0.88
Cardiac Arrest 10 (91%) 5 (71%) 0.52
SAVE score -5.9±2.4 -6.1±2.6 0.84
Table 1 Baseline Characteristics
Abbreviations: BMI: Body Mass Index, CAD: Coronary Artery Disease, LVEF: Left Ventricular 




There was a significant difference in the coronary anatomy between the two 
groups. The ECMO+IABP group tended to have more complex coronary anatomy 
when compared to the ECMO alone group. This is represented by a higher amount 
of either left main disease, left main plus three vessel disease or three vessel 
disease (ECMO alone 18% vs ECMO+IABP 86% p=0.03). This also represented by 
the higher SYNTAX score (ECMO alone 22 ±14 vs ECMO+IABP 32 ±13). (See table 2: 
Coronary anatomy)
 ECMO alone (n=11) ECMO + IABP (n=7) p Value
Culprit lesion   0.03
LAD 6 (54%) 0  
LCx 0 0  
RCA 3 (27%) 1 (14%)  
LM 2 (18%) 2 (29%)  
3-vessels PCI 0 2 (29%)  
LM+3 vessels disease 0 2 (29%)  
Syntax Score 22±14 32±13
Table 2 Coronary anatomy
Abbreviations: PCI: Percutaneous Coronary Intervention, LAD: Left Anterior Descending 
artery, LCx: Left Circumflex artery, RCA: Right Coronary Artery, LM: Left Main
Outcome
Survival to discharge was 72% (13/18) in the overall cohort. Survival to discharge 
in the ECMO+IABP group was significantly higher with 100% (7/7) when compared 
to the ECMO alone group where survival to discharge was 55% (6/11) p=0.035. 
A greater number of patients in the ECMO+IABP group have reached the one 
year survival point in the follow up period (ECMO alone 36% vs ECMO+IABP 86% 
p=0.04). Of the patients that died, most died on ECMO and in the hospital (80% 
(4/5). One of the patients in the ECMO alone group suffered major neurological 
impairment due to prolonged resuscitation and died after discharge due to 
aspiration pneumonia. Good neurological outcome was achieved in more patients 
in the ECMO+IABP group (ECMO alone 45% vs ECMO+IABP 100% p=0.037). 
However if this is calculated for the survivors only , leaving out deceased patients 
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this difference was not significant (ECMO alone 83% vs ECMO+IABP 100% p=0.26). 
Complete revascularization was achieved equally in the two groups (82% vs 86% 
p=0.99). LVEF did not differ between the two groups, with only a small amount of 
patients having a preserved ejection fraction after treatment (9% vs 14% p=0.34). 
(See table 3: Outcome)
 ECMO alone (n=11) ECMO + IABP (n=7) p Value
Survival total 6 (55%) 7 (100%) 0.035
Survival at 1-year 
Follow-up
4 (36%)^ 6 (86%) 0.04
In-hospital Death 4 (36%) 0 0.12
Death on ECMO 4 (36%) 0 0.12
Good Neurological 
Outcome (CPC 1-2)*
5 (45%)  7 (100%) 0.037
Complete 
revascularization
9 (82%) 6 (86%) 0.99
LVEF post procedure   0.34
Preserved (>50%) 1 (9%) 1 (14%)  
Moderate 
Dysfunction (35-40%)
3 (27%) 4 (57%)  
Severe Dysfunction 
(<35%)
7 (64%) 2 (29%)  
Table 3 Outcome
*If calculated for survivors alone p=0.26, ^One patient died during follow up period after 
reaching 1 year survival point. 
Length of stay and laboratory findings
With regard to length of ECMO treatment (4.9±2.8 vs 4.5±2.1 p=0.77) , days spent in 
the Intensive care unit (21.5±23.8 vs 17.3±12.6 p=0.70) or length of hospitalisation 
there was no difference between the ECMO alone group and the ECMO+IABP group. 
There was also no difference in the haematocrit (0.39±0.05 vs 0.45±0.06 p=0.18), 
platelet count (205±53 x109/L vs 267±10 x109/L p=0.14), Ph (7.14±0.16 mmol/L vs 
7.31±0.11 mmol/L p=0.42) and lactate levels (8.57±5.5 mmol/L vs 3.7±1.7 mmol/L 
p=0.06) post procedurally. There is was however a higher haemoglobin count in 
the ECMO alone group (8.2±1.1 mmol/L  vs 10.1±1.5 mmol/L p=0.009). (See Table 4: 
Length of stay and laboratory findings)  
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 ECMO alone (n=11) ECMO + IABP (n=7) p Value
Days on ECMO 4.9±2.8 4.5±2.1 0.77
Days in ICU 21.5±23.8 17.3±12.6 0.70




Haematocrit 0.39±0.05 0.45±0.06 0.18
Platelets (x109/L) 205±53 267±10 0.14
pH 7.14±0.16 7.31±0.11 0.42
Lactate (mmol/L) 8.57±5.5 3.7±1.7 0.06
Table 4 Length of stay and laboratory findings.
Safety aspects
From a safety perspective there was no statistical difference between the two 
groups. Thromboembolic complications occurred in 27% of the ECMO alone group 
and one patient in that group also had an infected cannula. In the ECMO+IABP 
group there were no observed thromboembolic complications. However this was 
not statistically significant (p=0.55).  Haemorrhagic complications occurred in 28% 
in the ECMO alone group, compared to 43% in the ECMO+IABP group (p=0.28). In 
neither of the groups was there any ECMO hardware malfunction observed.  (see 
table 5: Safety aspects)
 ECMO alone (n=11) ECMO + IABP (n=7) p Value
Complications   0.55
Embolism peripheral 0 0  
Embolism central 0 0  
Embolism air 0 0  
Leg-ischemia 3(27%) 0  
Infection 1(9%) 0  
Bleeding 2(18%) 3(43%) 0.28
Surgical Site 2(18%) 2(29%)  
Cannula Site 0 1(14%)  
Cerebral bleeding 0 0  
Hardware failure 0 0 1.0
Table 5 Safety Aspects




This study suggests that the combination of IABP and ECMO is associated with 
better outcome than ECMO alone in the treatment of cardiogenic shock. 
The difference in outcome between the two groups could be a result of the LV 
unloading by the IABP. As all other organs are perfused by the ECMO circuit the 
IABP reduces the afterload for the LV and this may reduce infarct size. There is 
however no difference in the post procedural EF in this study. It could also improve 
survival through a mechanism of increased coronary perfusion with oxygenated 
blood from the ECMO circuit. In the absence of an IABP blood ejected from the 
heart goes through the pulmonary circulation. In the case of cardiogenic shock 
there may be overt pulmonary congestion causing desaturated blood being 
ejected from the LV into the coronary arteries. This can cause a harlequin effect and 
inadequate coronary perfusion. The use of an IABP may lead to better dispersion 
of oxygen rich blood through the aorta facilitating adequate coronary artery 
perfusion. This same mechanism may apply to cerebral perfusion. Concomitant 
IABP in addition to ECMO may increase cerebral perfusion and increase a good 
neurological outcome. Although no statistical proof-of-principle n this study all 
patients who received this technique had good neurological outcome.
The Syntax score in the ECMO+IABP group is higher than in the ECMO alone 
group. A higher syntax score aids in decision making between either PCI or 
coronary artery bypass surgery. In the case of STEMI, especially when there is 
profound cardiogenic shock, primary PCI is the treatment of choice. The more 
complex anatomy in the ECMO+IABP group did not lead to either worse outcome 
nor did it lead to less complete revascularization. This may be explained trough 
the mechanism that while a patient is on ECMO there is adequate hemodynamic 
support which may facilitate a more complex coronary intervention.  A higher 
SYNTAX score is also a predictor for major adverse cardiovascular and cerebral 
events with a cutoff of 34. Yet in this study there is no observed difference between 
the two groups in regard to safety outcome. A possible explanation may be that 
concomitant use of ECMO and IABP may lead to better overall hemodynamics and 
so prevents complications. 
The predicted morality as assessed by the SAVE score in this study was equally 
high in both groups. All patients were in Killip class 4. Both these findings suggest a 
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low predicted survival rate of between 15-35%. Yet in both groups actual survival is 
much higher. This may be an indication that both techniques may  be successfully 
used in the treatment of cardiogenic shock in STEMI. Al large number of patients 
suffered a cardiac arrest prior to receiving mechanical circulatory support. Yet 
outcome is still good in the overall group and more specifically in the ECMO+IABP 
group. This underlines that after the finding that routine IABP implantation alone 
did not improve survival, ECMO and concomitant IABP implantation may be the 
way forward in treating cardiogenic shock associated with STEMI. 
The form of LV unloading in this study is IABP. As mentioned before, other 
strategies are also possible. The advantage of using the IABP is that it’s use and 
availability is wide spread and it is therefore readily available in many hospitals 
around the world. It is also relatively cheap compared to, for example, Impella. 
Also, Impella is not reimbursed in various countries making this a costly approach 
to LV unloading. Furthermore IABP is less invasive, specifically when compared 
to surgical LV venting, and can even be used through the ECMO cannula with of 
label use of a Y-connector.  It can be used if there is severe aortic stenosis and it is 
difficult to pass the aortic valve. 
The length of hospitalization and treatment did not differ between the groups. Yet 
time spent in hospital was considerable  for both groups of nearly a month. This 
implicates that these high complex patients with serious acute life threatening 
disease should ideally be treated in dedicated tertiary care centers with not only 
expertise on ECMO, IABP and PCI but also in patient and family guidance as these 
treatments can be very traumatizing for patients as well as their next of kin. In 
regard to the laboratory findings there is  a lower Hb level in the ECMO alone 
group. ECMO can cause haemolysis and reduce Hb which could explain this 
finding. It was however not observed in the ECMO+IABP group. There is a trend 
towards lower lactate levels in the ECMO+IABP group which could be explained by 
the better hemodynamic support of this combined form of mechanical circulatory 
support. However, it could also be that the patients in the ECMO+IABP group were 
just less sick.
The complication rate is relatively low in this group. Limb ischemia is a known 
complication and can be prevented by several things. First, cannulation should 
ideally be performed in both groins. Where the arterial and venous cannula are 
each at a different groin preventing simultaneous decreased perfusion of the leg 
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due to arterial blockage and stasis of the blood due to venous occlusion by the 
cannula. Second, antegrade perfusion of the leg should be routinely performed to 
insure perfusion of the leg. Distance between antegrade and retrograde arterial 
cannula’s should be as short as possible to prevent clot formation at this site. 
Recently a meta analysis was published by Russo et al demonstrating a benefit of 
LV unloading for the outcome in the treatment of cardiogenic shock. This study 
showed a benefit of all forms of unloading. However it did not discern between 
the different etiologies of cardiogenic shock. Our studies corroborates this data 
but adds to this that in the specific case of STEMI, LV unloading using the IABP in 
the setting of VA-ECMO support is beneficial [21].    
LIMITATIONS
There are several limitations  to this study. It is an observational study with a limited 
number of patients. Bias and unknown confounders may have caused the lower 
observed mortality in the ECMO + IABP group. However, the lower mortality was 
observed even with the patients in the ECMO + IABP group having more severe 
coronary artery disease. There is also operator bias in selecting patients eligible 
for mechanical circulatory support.  Only comparative statistics were used in this 
study making it difficult to establish causality
However, to our knowledge this is the first study demonstrating a possible survival 
benefit of ECMO with concomitant IABP in the setting of STEMI complicated by 
cardiogenic shock. Future studies are required to establish the benefit of this 
technique in this group of patients, preferably in a randomized controlled design. 
Interpretation of this study must be done with caution. It is hypothesis generating 
but it is difficult to apply in daily practice. Hopefully it will be possible to perform a 
randomized controlled trial in the future to establish a true survival benefit. 
CONCLUSION
In this small observational study it is shown that VA-ECMO might be able to 
improve survival in patients with cardiogenic shock due to STEMI even when in 
cardiac arrest. This observation suggests that VA-ECMO in combination with IABP 
is associated with higher survival than VA-ECMO alone and is also associated 
with good neurological outcome. It is also associated with better outcome in 
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more complex coronary artery anatomy.  However, the data presented is purely 
exploratory and warrants cautiousness in its interpretation. Physiological studies 
are required to prove the effectiveness of this technique and to facilitate a future 
randomized controlled trial.
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This thesis has demonstrated  that the incidence of infective endocarditis is rising. 
Despite great advances in imaging modalities, antibiotic treatment and surgical 
technique we have not been able to reduce mortality in this devastating disease 
and it still ranks amongst the most lethal infectious diseases in the western world. 
Future studies should focus on early detection and novel imaging modalities. An 
example of this is the use of Positron Emission Tomography (PET). The PET scan is 
increasingly being used to detect prosthetic valve endocarditis at an early stage. 
Hopefully this will develop further and as such will influence prognosis through 
a mechanism of early detection of possible complications and prompt surgical 
intervention. 
The ever ongoing debate on whether chemoprophylaxis is useful in preventing 
infective endocarditis should also be settled. However, as this debate has been 
going on for many years already I greatly fear it might never be completely settled 
at all. The evidence in favor of chemoprophylaxis is robust. The evidence against 
chemoprophylaxis is robust as well. Possibly a future randomized controlled trial 
will bring forth enough evidence to make sound recommendations on this subject. 
Infectious endocarditis has a very high mortality, even more so in the population 
affected in general hospitals. The reasons for this phenomenon are unclear. As most 
studies concentrate on tertiary centers, general hospitals are underrepresented in 
previous literature and there is selection bias. This may be the key in improving 
outcome; perform more studies in general hospitals in an all-comer real world 
population.  
The treatment of cardiogenic shock is difficult. VA-ECMO may be a solution for 
this problem. A randomized controlled trial in a similar fashion as the IABP-SHOCK 
trial may provide answers. In facilitating high risk percutaneous intervention it can 
be used safely and effectively. A head to head comparison with other mechanical 
circulatory support devices, such as the Impella  device, may determine the best 
strategy. Future studies should concentrate on drawing conclusions from making 
such a comparison. 
Another issue that needs to be addressed is how to reduce afterload for the left 
ventricle when patients are on VA-ECMO. Current strategies are the concomitant 
Future perspectives en Nederlandse Samenvatting 
10
147 
use of ECMO and Impella or ECMO and IABP. Both seem to influence outcome in 
a positive way. Animal studies, preferably with LV pressure volume loops should 
(could?) confirm the best strategy. Future human studies should confirm the 
animal results and provide an answer to the question: what is the best strategy in 
mechanical circulatory support?
However we must not forget that it is not all roses when it comes to ECMO as 
a means for circulatory support. The outcome in patients who receive ECMO 
support after cardiac surgery for infective endocarditis is disappointing, to put it 
mildly. This echoes the result of other studies in this thesis that despite medical 
progress we still struggle to treat this devastating infectious disease. 
In all, this thesis answers some question but raises more. It is my great desire to 
answer these questions in the future. 
 
NEDERLANDS SAMENVATTING 
Het voor u liggende proefschrift getiteld “Intra-cardiale infecties, coronaire 
interventies en mechanische circulatoire ondersteuning” handelt over de volgende 
zaken:
In het eerste hoofdstuk wordt de opbouw van het proefschrift uitgelegd. Daarna 
wordt in het tweede hoofdstuk van het proefschrift beschreven hoe de uitkomst 
is van patiënten met infectieuze endocarditis die zich in een algemeen ziekenhuis 
presenteren. Het meeste onderzoek naar endocarditis vindt plaats in tertiaire 
centra en dat kan de uitkomst in deze groep patiënten vertekenen. We zien 
dat patiënten in algemene ziekenhuizen die zich presenteren een veel hogere 
mortaliteit hebben dan vergelijkende studies in tertiaire ziekenhuizen. Ook zien 
we dat vrouwelijke patiënten, patiënten met een kunstklep en oudere patiënten 
het aanzienlijk slechter doen. Daarnaast toont deze studie aan dat een infectieuze 
endocarditis met een Staphylococcus  Aureus bacterie een gecompliceerder 
beloop kent dan endocarditis veroorzaakt door andere bacteriën. 
Het derde hoofdstuk is opgedeeld in twee delen. In het eerste deel wordt 
aangetoond dat sinds de versoepelingen van en endocarditis profylaxe richtlijnen 
in 2009 we een toename zien van het aantal gevallen van infectieuze endocarditis. 
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Deze toename is meer dan op de eerdere historische trend te verwachten was en 
zou dus verband kunnen houden met de versoepeling van die eerder genoemde 
profylaxe richtlijnen. Daarnaast zien we gelijktijdig met deze versoepeling een 
toename van het aantal Streptokok remedieerde endocarditis en dit is juist de 
bacterie waarvoor de profylaxe wordt gegeven. In het tweede deel van hoofdstuk 
drie wordt een pleidooi gehouden voor het opnieuw overwegen van de indicatie 
van en profylaxe om zo de stijging van het aantal gevallen van endocarditis tot 
staan te brengen. 
In hoofdstuk vier wordt een nieuwe strategie beschreven om patiënten te 
behandelen met een pacemaker infectie die gelijktijdig van deze pacemaker 
afhankelijk zijn. Bij deze patiënten wordt in een sessie de geïnfecteerde 
endovasculaire pacemaker verwijderd waarna er een epicardiale pacemaker 
draad op het hart wordt geplaats om zo de pacing te borgen. De peri-procedurele 
complicaties zijn laag een deze techniek blijkt effectief, veilig en toepasbaar te zijn. 
In hoofdstuk vijf wordt een studie beschreven naar de incidentie en uitkomst van 
endocarditis van de aortklepprothese na trans-katheter aortaklep vervanging. 
Deze studie, uitgevoerd in negen ziekenhuizen laat zien dat hoewel de incidentie 
laag is de uitkomst in deze groep patiënten slecht is. 
 Hoofdstuk zes is wederom opgedeeld in twee delen. In het eerste deel wordt een 
groep patiënten beschreven die infectieuze endocarditis hebben en ten gevolgen 
van ernstig acuut hartfalen behandeld moeten worden met extra corporele 
membraan oxygenatie. De uitkomst in deze groep patiënten is slecht en het is de 
vraag of deze nieuwe techniek toepassing heeft in deze specifieke populatie. Het 
tweede deel van hoofdstuk zes laat een patiënt zien waarin door middel van trans 
thoracale echo een repositie van de veno veneuze extra corporele membraan 
oxygenatie canule heeft plaatsgevonden met verbetering van de klinische conditie 
van de patiënt. 
Hoofdstuk zeven beschrijft hoe veno-arteriele extra corporele membraan 
oxygenatie gebruikt kan worden bij patiënten in cardiogene shock tijdens een ST-
elevatie myocard infarct. Door het toepassen van deze techniek kan een hogere 
overleving dan voorspeld worden bereikt, zelf als patiënten in een reanimatie 
setting komen. Mogelijk is de beschreven techniek en strategie een alternatief 
voor de intra-aortale ballon pomp die inmiddels een groot deel van zijn indicatie is 
kwijt geraakt in de behandeling van cardiogene shock. 
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Hoofdstuk 8 beschrijft het gebruik van veno-arteriele extra corporele membraan 
oxygenatie als ondersteuning van het hart gedurende electieve hoog risico 
percutane interventies aan de coronair arteriën. De uitkomst in deze groep 
patiënten is goed en deze strategie van mechanische ondersteuning is vellig en 
effectief. 
Het laatste hoofdstuk behandeld het gebruik van veno-arteriele extra corporele 
membraan oxygenatie in combinatie met een intra-aortale ballon pomp en 
vergelijking met veno-arteriele extra corporele membraan oxygenatie alleen 
in de behandeling van cardiogene shock bij ST-elevatie myocardinfarct. Omdat 
veno-arteriele extra corporele membraan oxygenatie de afterload van de linker 
kamer verhoogd zou de dit uitkomst negatief kunnen beïnvloeden bij deze groep 
patiënten. Als er gelijktijdig een intra-aortale ballon pomp gebuikt wordt verlaagt 
dit de afterload van de linker kamer en zou dit de uitkomst positief kunnen 







In this section the impact of the research describe in this thesis will be discussed. 
It will also include a summary of its main findings for the non-medical reader, the 
implications for patients and medical professionals and the contribution of this 
thesis to the scientific field.
 
SUMMARY OF THE FINDINGS FOR THE NON-
MEDICAL READER
Infective endocarditis is a disease where part of the inner side of the heart is 
infected with bacteria. This can be a native structure (like a heart valve) but it can 
also be prosthetic material (like a pacemaker lead or a prosthetic heart valve). It 
is a dangerous disease with high mortality, as demonstrated in this thesis. One of 
the ways infective endocarditis can be prevented is by administering antibiotics 
prior to certain procedures (like dental procedures) when you have an abnormal 
heart valve. In 2009 the indication for this prophylaxis was changed. The result 
was that less patients were eligible for this prophylaxis. Since that time there has 
been an increase in infective endocarditis above the expected historical trend. 
It is possible for patients to not have a heart rhythm of their own. If this is the case 
they need a pacemaker. This pacemaker is usually placed in the venous system on 
the right side of the heart. A possible complication of having a pacemaker is that it 
gets infected with a bacteria. In that case the pacemaker will have to be removed. 
However, if a patient has no underlying heart rhythm they cannot live without a 
pacemaker. If you place a pacemaker on the outside of the heart and the remove 
the infected pacemaker you will ensure pacing of the heart. This technique is safe 
and feasible. 
Infective endocarditis can also affect prosthetic heart valves that have been 
implanted via a catheter through the arteries in the groin. This is a rare complication 
and it is rarer than endocarditis of a surgically implanted heart valve. Yet when you 
do attract it, outcome is poor. 
Patient who contract endocarditis can be very sick. They can be so sick that their 
heart is no longer possible to keep them alive. A possible treatment for this is 




of heart lung machine for prolonged use. It can be used in patients with infective 
endocarditis, however, outcome is poor. 
The same VA-ECMO technique can be used in patients who a suffer from an acute 
heart attack. These patients can develop acute heart failure due to occlusion of 
one of the arteries of the heart. They can even develop cardiac arrest. VA-ECMO 
can improve survival in these patients and ensure adequate blood flow to the 
organs when the heart is no longer able to do so. 
If patients need to undergo an elective procedure in which a stent in placed in one 
of the arteries of the heart and they have poor contractility of the heart muscle they 
can develop acute heart failure during the procedure. The use of VA-ECMO prior 
to this procedure in a prophylactic fashion is safe and can be effectively used to 
prevent acute heart failure and ensure organ perfusion during these procedures. 
Finally we demonstrate that the combined use of VA-ECMO and the intra-aortic 
balloon pump improves survival in acute myocardial infarction when compared to 
the use of VA-ECMO alone.
SCIENTIFIC IMPACT AND IMPACT FOR PATIENTS
This thesis has made it clear that mortality from infective endocarditis is high 
and that early referral may improve survival. It also demonstrates that there may 
be need to expand the indication for chemoprophylaxis in preventing infective 
endocarditis. Patients who are pacemaker dependent and have an infected device 
now have a safe extraction and re-implantation strategy which ensures permanent 
pacing. Patient who have undergone a trans catheter aortic valve implantation are 
now assured that the risk of infective endocarditis is low. However, if the do attract 
it outcome is poor. 
Patients who are in cardiogenic shock, especially when suffering from ST-elevation 
myocardial infarction can be safely treated with VA-ECMO. This can improve survival 
and could be considered by interventional cardiologists when encountering these 
patients in clinical practice. They could also consider using VA-ECMO when they 
perform high risk percutaneous interventions in order to prevent cardiogenic 
shock. However, if prolonged use of VA-ECMO is indicated in patients who have 
developed cardiogenic shock due to ST-elevation myocardial infarction afterload 
reduction with the intra-aortic balloon pump as an afterload device is advisable. 
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